NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
CONTENTS |
|---|
|
|
|---|
Preface
Introduction
Definition and Classification of Severity
Definition
Classification of Severity
Pathogenesis
Pathology
Pathophysiology
Burden of COPD
Epidemiology
Economic and Social Burden of COPD
Risk Factors
The Four Components of COPD Management
Introduction
Component 1: Assess and Monitor Disease
Diagnosis
Ongoing Monitoring and Assessment
Component 2: Reduce Risk Factors
Smoking Prevention and Cessation
Occupational Exposures
Indoor/Outdoor Air Pollution
Component 3: Manage Stable COPD
Introduction
Education
Pharmacologic Treatment
Bronchodilators
Glucocorticosteroids
Other Pharmacologic Treatments
Nonpharmacologic Treatment
Rehabilitation
Oxygen Therapy
Ventilatory Support
Surgical Treatments
Component 4: Manage Exacerbations
Diagnosis and Assessment of Severity
Home Management
Hospital Management
Hospital Discharge and Follow-up
Future Research
References
| |
PREFACE |
|---|
|
|
|---|
Chronic obstructive pulmonary disease (COPD) is a major public health problem. It is the fourth leading cause of chronic morbidity and mortality in the United States (1) and is projected to rank fifth in 2020 as a worldwide burden of disease according to a study published by the World Bank/World Health Organization (2). Yet, COPD fails to receive adequate attention from the health care community and government officials. With these concerns in mind, a committed group of scientists encouraged the U.S. National Heart, Lung, and Blood Institute and the World Health Organization to form the Global Initiative for Chronic Obstructive Lung Disease (GOLD). Among GOLD's important objectives are to increase awareness of COPD and to help the thousands of people who suffer from this disease and die prematurely from COPD or its complications.
The first step in the GOLD program was to prepare a consensus Workshop Report, Global Strategy for the Diagnosis, Management, and Prevention of COPD. The GOLD Expert Panel, a distinguished group of health professionals from the fields of respiratory medicine, epidemiology, socioeconomics, public health, and health education, reviewed existing COPD guidelines, as well as new information on pathogenic mechanisms of COPD as they developed a consensus document. Many recommendations will require additional study and evaluation as the GOLD program is implemented.
A major problem is the incomplete information about the causes and prevalence of COPD, especially in developing countries. While cigarette smoking is a major known risk factor, much remains to be learned about other causes of this disease. The GOLD Initiative will bring COPD to the attention of governments, public health officials, health care workers, and the general public, but a concerted effort by all involved in health care will be necessary to control this major public health problem.
I would like to acknowledge the dedicated individuals who prepared the Workshop Report and the effective leadership of the Workshop Chair, Professor Romain Pauwels. It is a privilege for the National Heart, Lung, and Blood Institute to serve as one of the cosponsors. We look forward to working with the World Health Organization, and all other interested organizations and individuals, to meet the goals of the GOLD Initiative.
Development of the Workshop Report was supported through educational grants to the Department of Respiratory Diseases of the Ghent University Hospital, Belgium (WHO Collaborating Center for the Management of Asthma and COPD) from ASTA Medica, AstraZeneca, Aventis, Bayer, Boehringer-Ingelheim, Byk Gulden, Chiesi, Glaxo Wellcome, Merck, Sharp & Dohme, Mitsubishi-Tokyo, Nikken Chemicals, Novartis, Schering-Plough, SmithKline Beecham, Yamanouchi, and Zambon.
CLAUDE LENFANT, M.D.
Director
National Heart, Lung, and Blood Institute
| |
INTRODUCTION |
|---|
|
|
|---|
Chronic obstructive pulmonary disease (COPD) is a major cause of chronic morbidity and mortality throughout the world. COPD is currently the fourth leading cause of death in the world (3), and further increases in the prevalence and mortality of the disease can be predicted in the coming decades. A unified international effort is required to reverse these trends.
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) is a collaborative project of the U.S. National Heart, Lung, and Blood Institute (NHLBI) and the World Health Organization (WHO). Its goals are to increase awareness of COPD and decrease morbidity and mortality from this disease. GOLD aims to improve prevention and management of COPD through a concerted worldwide effort of people involved in all facets of health care and health care policy, and to encourage a renewed research interest in this extremely prevalent disease.
The GOLD Workshop Report, Global Strategy for the Diagnosis, Management, and Prevention of COPD, presents a COPD management plan with four components: (1) Assess and Monitor Disease; (2) Reduce Risk Factors; (3) Manage Stable COPD; (4) Manage Exacerbations. The Workshop Report is based on the best-validated current concepts of COPD pathogenesis and the available evidence on the most appropriate management and prevention strategies. It has been developed by individuals with expertise in COPD research and patient care and extensively reviewed by many experts and scientific societies. Before its release for publication, the Workshop Report was reviewed by the NHLBI and the WHO. This Executive Summary provides key information about COPD; the full Workshop Report provides more details.
In Section 3, Four Components of COPD Management, levels of evidence are assigned to statements, where appropriate, using a system developed by the NHLBI (Table 1). Levels of evidence are indicated in parentheses after the relevant statement, e.g., (Evidence A).
|
| |
DEFINITION AND CLASSIFICATION OF SEVERITY |
|---|
|
|
|---|
Definition
COPD is a disease state characterized by airflow limitation that is not fully reversible. The airflow limitation is usually both progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases.
A diagnosis of COPD should be considered in any patient who has symptoms of cough, sputum production, or dyspnea, and/or a history of exposure to risk factors for the disease. The diagnosis is confirmed by spirometry. The presence of a postbronchodilator FEV1 < 80% of the predicted value in combination with an FEV1/FVC < 70% confirms the presence of airflow limitation that is not fully reversible. Where spirometry is unavailable, the diagnosis of COPD should be made using all available tools. Clinical symptoms and signs, such as abnormal shortness of breath and increased forced expiratory time, can be used to help with the diagnosis. A low peak flow is consistent with COPD, but has poor specificity because it can be caused by other lung diseases and by poor performance. In the interest of improving the diagnosis of COPD, every effort should be made to provide access to standardized spirometry. Chronic cough and sputum production often precede the development of airflow limitation by many years, although not all individuals with cough and sputum production go on to develop COPD.
Classification of Severity
For educational reasons, a simple classification of disease severity into four stages is recommended (Table 2). The management of COPD is largely symptom-driven, and there is only an imperfect relationship between the degree of airflow limitation and the presence of symptoms. The staging, therefore, is a pragmatic approach aimed at practical implementation and should only be regarded as an educational tool, and a very general indication of the approach to management. All FEV1 values refer to postbronchodilator FEV1.
|
Stage 0: At Risk. Characterized by chronic cough and sputum production. Lung function, as measured by spirometry, is still normal.
Stage I: Mild COPD. Characterized by mild airflow limitation (FEV1/FVC < 70% but FEV1
80% predicted) and usually, but not always, by chronic cough and sputum production.
At this stage, the individual may not even be aware that his or
her lung function is abnormal.
Stage II: Moderate COPD. Characterized by worsening airflow limitation (30%
FEV1 < 80% predicted) and usually
the progression of symptoms, with shortness of breath typically developing on exertion. This is the stage at which patients typically seek medical attention because of dyspnea or
an exacerbation of their disease. The division in Stages IIA
and IIB is based on the fact that exacerbations are especially
seen in patients with an FEV1 below 50% predicted. The presence of repeated exacerbations has an impact on the quality of
life of patients and requires appropriate management.
Stage III: Severe COPD. Characterized by severe airflow limitation (FEV1 < 30% predicted) or the presence of respiratory failure or clinical signs of right heart failure. Patients may have severe (Stage III) COPD even if the FEV1 is > 30% predicted, whenever these complications are present. At this stage, quality of life is appreciably impaired and exacerbations may be life-threatening.
Poorly reversible airflow limitation associated with bronchiectasis, cystic fibrosis, tuberculosis, or asthma is not included except insofar as these conditions overlap with COPD. In many developing countries both pulmonary tuberculosis and COPD are common. Therefore, in all subjects with symptoms of COPD, a possible diagnosis of tuberculosis should be considered, especially in areas where this disease is known to be prevalent. In countries in which the prevalence of tuberculosis is greatly diminished, the possible diagnosis of this disease is sometimes overlooked.
Pathogenesis
COPD is characterized by chronic inflammation throughout
the airways, parenchyma, and pulmonary vasculature. Macrophages, T lymphocytes (predominately CD8+), and neutrophils are increased in various parts of the lung. Activated inflammatory cells release a variety of mediators
including leukotriene B4 (LTB4) (4), interleukin-8 (IL-8) (5), tumor necrosis factor-
(TNF-
) (5, 8), and others
capable of damaging lung structures or sustaining neutrophilic inflammation. In addition to inflammation, two other processes thought to
be important in the pathogenesis of COPD are an imbalance
of proteinases and antiproteinases in the lung, and oxidative
stress. Inflammation of the lungs is caused by exposure to inhaled noxious particles and gases. Cigarette smoke can induce
inflammation and directly damage the lungs (9). Although
fewer data are available, it is likely that other COPD risk factors initiate a similar inflammatory process (15). It is believed that this inflammation can then lead to COPD.
Pathology
Pathologic changes characteristic of COPD are found in the
central airways, peripheral airways, lung parenchyma, and
pulmonary vasculature. In the central airways
the trachea,
bronchi, and bronchioles greater than 2 to 4 mm in internal diameter
inflammatory cells infiltrate the surface epithelium
(9, 20, 21). Enlarged mucus-secreting glands and an increase in
the number of goblet cells are associated with mucus hypersecretion. In the peripheral airways
small bronchi and bronchioles that have an internal diameter of less than 2 mm
chronic
inflammation leads to repeated cycles of injury and repair of
the airway wall (22). The repair process results in a structural
remodeling of the airway wall, with increasing collagen content and scar tissue formation, that narrows the lumen and
produces fixed airways obstruction (23).
Destruction of the lung parenchyma in patients with COPD typically occurs as centrilobular emphysema. This involves dilatation and destruction of the respiratory bronchioles (24). These lesions occur more frequently in the upper lung regions in milder cases, but in advanced disease they may appear diffusely throughout the entire lung and also involve destruction of the pulmonary capillary bed. An imbalance of endogenous proteinases and antiproteinases in the lung resulting from genetic factors or the action of inflammatory cells and mediators, is thought to be a major mechanism behind emphysematous lung destruction. Oxidative stress, another consequence of inflammation, may also contribute (25).
Pulmonary vascular changes in COPD are characterized by a thickening of the vessel wall that begins early in the natural history of the disease. Thickening of the intima is the first structural change (26), followed by an increase in smooth muscle and the infiltration of the vessel wall by inflammatory cells (27). As COPD worsens, greater amounts of smooth muscle, proteoglycans, and collagen (28) further thicken the vessel wall.
Pathophysiology
Pathologic changes in the lungs lead to corresponding physiologic changes characteristic of the disease, including mucus hypersecretion, ciliary dysfunction, airflow limitation, pulmonary hyperinflation, gas exchange abnormalities, pulmonary hypertension, and cor pulmonale. They usually develop in this order over the course of the disease. Mucus hypersecretion and ciliary dysfunction lead to chronic cough and sputum production. These symptoms can be present for many years before other symptoms or physiologic abnormalities develop. Expiratory airflow limitation, best measured through spirometry, is the hallmark physiologic change of COPD and the key to diagnosis of the disease. It is primarily caused by fixed airway obstruction and the consequent increase in airway resistance. Destruction of alveolar attachments, which inhibits the ability of the small airways to maintain patency, plays a smaller role.
In advanced COPD, peripheral airways obstruction, parenchymal destruction, and pulmonary vascular abnormalities reduce the lung's capacity for gas exchange, producing hypoxemia and, later on, hypercapnia. Pulmonary hypertension, which develops late in the course of COPD (Stage III: Severe COPD), is the major cardiovascular complication of COPD and is associated with the development of cor pulmonale and a poor prognosis (29). The prevalence and natural history of cor pulmonale in COPD are not yet clear.
| |
BURDEN OF COPD |
|---|
|
|
|---|
Epidemiology
Most of the information available on COPD prevalence, morbidity, and mortality comes from developed countries. Even in these countries, accurate epidemiologic data on COPD are difficult and expensive to collect. Prevalence and morbidity data greatly underestimate the total burden of COPD because the disease is usually not diagnosed until it is clinically apparent and moderately advanced. The imprecise and variable definitions of COPD have made it hard to quantify the morbidity and mortality of this disease in developed (30) and developing countries. Mortality data also underestimate COPD as a cause of death because the disease is more likely to be cited as a contributory than as an underlying cause of death, or may not be cited at all (31).
Prevalence. In the Global Burden of Disease Study conducted under the auspices of the WHO and the World Bank (2, 32), the worldwide prevalence of COPD in 1990 was estimated to be 9.34/1,000 in men and 7.33/1,000 in women. However, these estimates include all ages and underestimate the true prevalence of COPD in older adults. The prevalence of COPD is highest in countries where cigarette smoking has been, or still is, very common, whereas the prevalence is lowest in countries where smoking is less common, or total tobacco consumption per individual is low.
Morbidity. The limited data that are available indicate that morbidity due to COPD increases with age and is greater in men than women (1). COPD is responsible for a significant part of physician visits, emergency department visits, and hospitalizations.
Mortality. COPD is currently the fourth leading cause of death in the world (3), and further increases in the prevalence and mortality of the disease can be predicted in the coming decades (2, 32). In the United States, COPD death rates are very low among people younger than 45 yr of age but then increase with age, and COPD becomes the fourth or fifth leading cause of death among those over 45 (1).
Economic and Social Burden of COPD
Table 3 provides an understanding of the relative economic burden of COPD in four countries with Western styles of medical practice and social or private insurance structures. Similar data from developing countries are not available. The Global Burden of Disease Study (2, 32) estimated the fraction of mortality and disability attributable to major diseases and injuries using a composite measure of the burden of each health problem, the disability-adjusted life year (DALY = the sum of years lost because of premature mortality and years of life lived with disability, adjusted for the severity of disability). According to projections, COPD will be the fifth leading cause of DALYs lost worldwide in 2020 (in 1990 it ranked twelfth), behind ischemic heart disease, major depression, traffic accidents, and cerebrovascular disease (Table 4).
|
|
Risk Factors
Risk factors for COPD include both host factors and environmental exposures, and the disease usually arises from an interaction between these two types of factors. The host factor that
is best documented is a rare hereditary deficiency of
1-antitrypsin. Other genes involved in the pathogenesis of COPD
have not yet been identified. The major environmental factors
are tobacco smoke; heavy exposure to occupational dusts and
chemicals (vapors, irritants, and fumes); and indoor/outdoor
air pollution. The role of sex as a risk factor for COPD remains unclear. In the past, most studies showed that COPD
prevalence and mortality were greater among men than women
(33). More recent studies (1, 37) from developed countries
show that the prevalence of the disease is almost equal in men
and women, which probably reflects changing patterns of tobacco smoking. Some studies have in fact suggested that
women are more susceptible to the effects of tobacco smoke
than men (35, 38). This is an important question given the increasing rate of smoking among women in both developed
and developing countries.
Host Factors
Genes. It is believed that many genetic factors increase (or decrease) a person's risk of developing COPD. The genetic risk factor that is best documented is a rare hereditary deficiency of
1-antitrypsin (39). Premature and accelerated development of panlobular emphysema and decline in lung function
occurs in many smokers and nonsmokers with the severe deficiency, although smoking increases the risk appreciably.
Other genes involved in the pathogenesis of COPD have not
yet been identified.
Airway hyperresponsiveness. Asthma and airway hyperresponsiveness, identified as risk factors that contribute to the development of COPD (42), are complex disorders related to a number of genetic and environmental factors. How they influence the development of COPD is unknown. Airway hyperresponsiveness may also develop after exposure to tobacco smoke or other environmental insults and thus may be a result of smoking-related airway disease.
Lung growth. Lung growth is related to processes occurring during gestation, birth weight, and exposures during childhood (43). Reduced maximal attained lung function (as measured by spirometry) may identify individuals who are at increased risk for the development of COPD (48).
Exposures
Tobacco smoke. Cigarette smokers have a higher prevalence of lung-function abnormalities and respiratory symptoms, a greater annual rate of decline in FEV1, and higher death rates for COPD than nonsmokers. Pipe and cigar smokers have higher COPD morbidity and mortality rates than nonsmokers, although their rates are lower than those for cigarette smokers (49). Not all smokers develop clinically significant COPD, which suggests that genetic factors must modify each individual's risk. Passive exposure to cigarette smoke may also contribute to respiratory symptoms and COPD by increasing the lungs' total burden of inhaled particulates and gases (33, 50, 51). Smoking during pregnancy may also pose a risk for the fetus, by affecting lung growth and development in utero and possibly the priming of the immune system (47, 52).
Occupational dusts and chemicals. When the exposures are sufficiently intense or prolonged, occupational dusts and chemicals (vapors, irritants, fumes) can cause COPD independently of cigarette smoking and increase the risk of the disease in the presence of concurrent cigarette smoking (53). Exposure to particulate matter, irritants, organic dusts, and sensitizing agents can cause an increase in airway hyperresponsiveness (54), especially in airways already damaged by other occupational exposures, cigarette smoke, or asthma.
Outdoor and indoor air pollution. High levels of urban air pollution are harmful to persons with existing heart or lung disease. The role of outdoor air pollution in causing COPD is unclear, but appears to be small when compared with cigarette smoking. Indoor air pollution from biomass fuel, burned for cooking and heating in poorly vented dwellings, has been implicated as a risk factor for the development of COPD (55).
Infections. A history of severe childhood respiratory infection has been associated with reduced lung function and increased respiratory symptoms in adulthood (48). However, viral infections may be related to another factor, e.g., low birth weight, that itself is related to COPD.
Socioeconomic status. There is evidence that the risk of developing COPD is inversely related to socioeconomic status (65). It is not clear, however, whether this pattern reflects exposures to indoor and outdoor air pollutants, crowding, poor nutrition, or other factors that are related to socioeconomic status (64, 66).
| |
THE FOUR COMPONENTS OF COPD MANAGEMENT |
|---|
|
|
|---|
Introduction
An effective COPD management plan includes four components: (1) Assess and Monitor Disease; (2) Reduce Risk Factors; (3) Manage Stable COPD; (4) Manage Exacerbations.
The goals of effective COPD management are to:
These goals should be reached with a minimum of side effects from treatment, a particular challenge in patients with COPD where comorbidities are common. The extent to which these goals can be realized varies with each individual, and some treatments will produce benefits in more than one area. In selecting a treatment plan, the benefits and risks to the individual and the costs, direct and indirect, to the community must be considered. Patients should be identified before the end stage of the illness, when disability is substantial. However, the benefits of spirometric screening, of either the general population or smokers, are still unclear. Educating patients and physicians to recognize that cough, sputum production, and especially breathlessness are not trivial symptoms is an essential aspect of the public health care of this disease.
Reduction of therapy once symptom control has been achieved is not normally possible in COPD. Further deterioration of lung function usually requires the progressive introduction of more treatments, both pharmacologic and nonpharmacologic, to attempt to limit the impact of these changes. Acute exacerbations of signs and symptoms, a hallmark of COPD, impair patients' quality of life and decrease their health status. Appropriate treatment and measures to prevent further exacerbations should be implemented as quickly as possible.
Component 1: Assess and Monitor Disease
Key Points
|
80% predicted). This approach to defining
airflow limitation is a pragmatic one in view of the fact that
universally applicable reference values for FEV1 and FVC are
not available.
Assessment of severity. Assessment of severity (Table 2) is
based on the level of symptoms, severity of the spirometric abnormality, and the presence of complications such as respiratory failure and right heart failure.
Additional investigations. For patients in Stage II: Moderate COPD and beyond, the following additional investigations
may be useful:
1. Bronchodilator reversibility testing. Generally performed
only once, at the time of diagnosis, this test is useful to help rule out a diagnosis of asthma, to establish a patient's best attainable lung function, to gauge a patient's prognosis, and to guide treatment decisions. However, even patients who
do not show a significant FEV1 response to a short-acting
bronchodilator test can benefit symptomatically from long-term bronchodilator treatment.
2. Glucocorticosteroid reversibility testing. The simplest, and
potentially safest, way to identify patients most likely to respond to long-term glucocorticosteroid treatment is with a
treatment trial of inhaled glucocorticosteroids for 6 wk to 3 mo, using as criteria for glucocorticosteroid reversibility an
FEV1 increase of 200 ml and 15% above baseline (70, 71).
The response to glucocorticosteroids should be evaluated
with respect to the postbronchodilator FEV1 (that is, the
effect of treatment with inhaled glucocorticosteroids should
be in addition to that of regular treatment with a bronchodilator).
3. Chest X-ray. A chest radiograph is seldom diagnostic in
COPD unless obvious bullous disease is present, but it is
valuable in excluding alternative diagnoses. Computed tomography (CT) of the chest is not routinely recommended.
However, when there is doubt about the diagnosis of
COPD, high-resolution CT (HRCT) might help in the differential diagnosis. In addition, if a surgical procedure such
as bullectomy or lung volume reduction is contemplated, chest CT is helpful.
4. Arterial blood gas measurement. In advanced COPD, measurement of arterial blood gases is important. This test
should be performed in patients with FEV1 < 40% predicted or with clinical signs suggestive of respiratory failure
or right heart failure. Clinical signs of respiratory failure or
right heart failure include central cyanosis, ankle swelling,
and an increase in the jugular venous pressure. Clinical
signs of hypercapnia are extremely nonspecific outside of
acute exacerbations. Respiratory failure is indicated by
PaO2 < 8.0 kPa (60 mm Hg) with or without PaCO2 > 6.0 kPa (45 mm Hg) while breathing air at sea level. Measurement of arterial blood gases should be obtained by arterial
puncture; finger or ear oximeters for assessing SaO2 are less reliable.
5.
1-Antitrypsin deficiency screening. In patients who develop COPD at a young age (< 45 yr) or who have a strong
family history of the disease, it may be valuable to identify
coexisting
1-antitrypsin deficiency. This could lead to family screening and appropriate counseling.
Differential diagnosis. A major differential diagnosis is
asthma. In some patients with chronic asthma, a clear distinction from COPD is not possible using current imaging and
physiologic testing techniques. In these cases, current management is similar to that of asthma. Other potential diagnoses
are usually easier to distinguish from COPD (Table 6).
|
Ongoing Monitoring and Assessment
Monitor disease progression and development of complications. COPD is usually a progressive disease, and a patient's lung function can be expected to worsen over time, even with the best available care. Symptoms and objective measures of airflow limitation should be monitored for development of complications and to determine when to adjust therapy.
Follow-up visits should include a discussion of new or worsening symptoms. Spirometry should be performed if there is a substantial increase in symptoms or a complication. Measurement of arterial blood gas tensions should be performed in all patients with an FEV1 < 40% predicted or clinical signs of respiratory failure or right heart failure. Elevation of the jugular venous pressure and the presence of pitting ankle edema are often the most useful findings suggestive of right heart failure in clinical practice. Measurement of pulmonary arterial pressure is not recommended in clinical practice as it does not add practical information beyond that obtained from a knowledge of PaO2.
Monitor pharmacotherapy and other medical treatment. In order to adjust therapy appropriately as the disease progresses, each follow-up visit should include a discussion of the current therapeutic regimen. Dosages of various medications, adherence to the regimen, inhaler technique, effectiveness of the current regime at controlling symptoms, and side effects of treatment should be monitored.
Monitor exacerbation history. Frequency, severity, and likely causes of exacerbations should be evaluated. Increased sputum volume, acutely worsening dyspnea, and the presence of purulent sputum should be noted. Severity can be estimated by the increased need for bronchodilator medication or glucocorticosteroids and by the need for antibiotic treatment. Hospitalizations should be documented, including the facility, duration of stay, and any use of critical care or intubation.
Monitor comorbidities. In treating patients with COPD, it is important to consider the presence of concomitant conditions such as bronchial carcinoma, tuberculosis, sleep apnea, and left heart failure. The appropriate diagnostic tools (chest radiograph, electrocardiogram [ECG], etc.) should be used whenever symptoms (e.g., hemoptysis) suggest one of these conditions.
Component 2: Reduce Risk Factors
Key Points
and cost-effective
way to reduce the risk of developing COPD and
stop its progression (Evidence A).
and
cost-effective
way to reduce the risk of developing COPD
and stop its progression. Even a brief, 3-min period of counseling to urge a smoker to quit can be effective, and at the very
least this should be done for every smoker at every visit (72,
73). Health education, public policy, and information dissemination programs are all vital components in a comprehensive
cessation effort.
Guidelines for smoking cessation. Guidelines for smoking
cessation were published by the U.S. Agency for Health Care
Policy and Research (AHCPR) in 1996 (74) and updated in
2000 by the U.S. Public Health Service in Treating Tobacco
Use and Dependence: A Clinical Practice Guideline (75).
Smoking cessation intervention process. The Public Health
Service Report recommends a five-step program for intervention
(Table 7), which provides a strategic framework helpful to health
care providers interested in helping their patients stop smoking.
Three types of counseling are especially effective: practical counseling, social support as part of treatment, and social support arranged outside of treatment (74) (Evidence A).
|
Component 3: Manage Stable COPD
Key Points
2-agonists, anticholinergics, theophylline, and a combination of one or
more of these drugs (Evidence A).
|
|
2-agonists, anticholinergics, and methylxanthines,
are shown in Table 10. The choice depends on the availability
of the medication and the patient's response. All categories of
bronchodilators have been shown to increase exercise capacity
in COPD, without necessarily producing significant changes in
FEV1 (99) (Evidence A). Regular treatment with short-acting bronchodilators is cheaper but less convenient than
treatment with long-acting bronchodilators. The long-acting,
inhaled
2-agonist salmeterol has been shown to improve
health status significantly in doses of 50 µg twice daily (102)
(Evidence B). Similar data for short-acting
2-agonists are not
available. Use of inhaled ipratropium (an anticholinergic) four
times daily also improves health status (Evidence B) (103). Theophylline is effective in COPD, but because of its potential toxicity, inhaled bronchodilators are preferred when available. All studies that have shown efficacy of theophylline in COPD
were done with slow-release preparations.
|
2-agonist and the anticholinergic drug ipratropium in stable COPD produces greater and more sustained improvements in FEV1 than either alone and does not produce
evidence of tachyphylaxis over 90 d of treatment (104)
(Evidence A). Combination of a
2-agonist, an anticholinergic, or theophylline may produce additional improvements
in lung function (104, 107) and health status (101, 104,
107, 110). Increasing the number of drugs usually increases
costs, and an equivalent benefit may occur by increasing the
dose of one bronchodilator when side effects are not a limiting
factor. Detailed assessments of this approach have not been
carried out.
Increasing the dose of either a
2-agonist or an anticholinergic, especially when given by a wet nebulizer, appears to
provide subjective benefit in acute episodes (111) (Evidence
B). Some patients may request regular treatment with high-dose, nebulized bronchodilators (112), especially if they have
experienced subjective benefit from this treatment during an
acute exacerbation. Clear scientific evidence for this approach
is lacking, but one option is to examine the improvement in
mean daily peak expiratory flow (PEF) recording during 2 wk
of treatment in the home and continue with nebulizer therapy
if a significant improvement occurs (112). In general, nebulized therapy for a stable patient is not appropriate unless it
has been shown to be better than conventional dose therapy.
Glucocorticosteroids. Prolonged treatment with inhaled
glucocorticosteroids does not modify the long-term decline in
FEV1 in patients with COPD (91). Regular treatment with
inhaled glucocorticosteroids is only appropriate for symptomatic COPD patients with a documented spirometric response
to inhaled glucocorticosteroids (see Component 1) or in those
with FEV1 < 50% predicted (Stage IIB: Moderate COPD and
Stage III: Severe COPD) and repeated exacerbations requiring treatment with antibiotics or oral glucocorticosteroids (91-
94) (Evidence B). The dose-response relationships and long-term safety of inhaled glucocorticosteroids in COPD are not
known. The present guidelines recommend a trial of 6 wk to
3 mo with inhaled glucocorticosteroids to identify COPD patients who may benefit from long-term inhaled glucocorticosteroid therapy. Many existing COPD guidelines recommend the use of a short course (2 wk) of oral glucocorticosteroids to
identify patients with COPD who might benefit from long-term treatment with oral or inhaled glucocorticosteroids.
There is mounting evidence, however, that a short course of
oral glucocorticosteroids is a poor predictor of the long-term
response to inhaled glucocorticosteroids in COPD (93, 113).
Long-term treatment with oral glucocorticosteroids is not
recommended in COPD (114) (Evidence A). There is no
evidence of long-term benefit from this treatment. Moreover,
a side effect of long-term treatment with systemic glucocorticosteroids is steroid myopathy (115, 116), which contributes to
muscle weakness, decreased functionality, and respiratory failure in patients with advanced COPD.
Other Pharmacologic Treatments
Vaccines. Influenza vaccines can reduce serious illness and death in patients with COPD by approximately 50% (117). Vaccines containing killed or live, inactivated viruses are recommended (118), and should be given once (in autumn) or twice (in autumn and winter) each year (Evidence A). A pneumococcal vaccine containing 23 virulent serotypes has been used but sufficient data to support its general use in COPD patients are lacking (119) (Evidence B).
1-Antitrypsin augmentation therapy. Young patients with
severe hereditary
1-antitrypsin deficiency and established emphysema may be candidates for
1-antitrypsin augmentation
therapy. However, this therapy is very expensive, is not available in most countries, and is not recommended for COPD
that is not related to
1-antitrypsin deficiency (Evidence C).
Antibiotics. The use of antibiotics, other than in treating infectious exacerbations of COPD and other bacterial infections, is not recommended (122, 123) (Evidence A).
Mucolytic (mucokinetic, mucoregulator) agents. (ambroxol, erdosteine, carbocysteine, iodinated glycerol): Although a few patients with viscous sputum may benefit from mucolytics (124, 125), the overall benefits seem to be very small. Therefore, the widespread use of these agents cannot be recommended on the basis of the present evidence (Evidence D).
Antioxidant agents. Antioxidants, in particular N-acetylcysteine, have been shown to reduce the frequency of exacerbations and could have a role in the treatment of patients with recurrent exacerbations (126) (Evidence B). However, before their routine use can be recommended, the results of ongoing trials will have to be carefully evaluated.
Immunoregulators (immunostimulators, immunomodulators). A study using an immunostimulator in COPD showed a decrease in the severity (though not in the frequency) of exacerbations (130), but these results have not been duplicated. Thus, the regular use of this therapy cannot be recommended based on the present evidence (131) (Evidence B).
Antitussives. Cough, although sometimes a troublesome symptom in COPD, has a significant protective role (132). Thus, the regular use of antitussives is contraindicated in stable COPD (Evidence D).
Vasodilators. In patients with stable COPD, inhaled nitric oxide can worsen gas exchange because of altered hypoxic regulation of ventilation-balance (133, 134) and thus is contraindicated.
Respiratory stimulants. The use of doxapram, a nonspecific respiratory stimulant available as an intravenous formulation, is not recommended in stable COPD (Evidence D). Almitrine bismesylate is not recommended for regular use in stable COPD patients (135) (Evidence B).
Narcotics. Narcotics are contraindicated in COPD because of their respiratory depressant effects and potential to worsen hypercapnia. Clinical studies suggest that morphine used to control dyspnea may have serious adverse effects and its benefits may be limited to a few sensitive subjects (138). Codeine and other narcotic analgesics should also be avoided.
Others. Nedocromil, leukotriene modifiers, and alternative healing methods (e.g., herbal medicine, acupuncture, homeopathy) have not been adequately tested in COPD patients and thus cannot be recommended at this time.
Nonpharmacologic Treatment
Rehabilitation. The principal goals of pulmonary rehabilitation are to reduce symptoms, improve quality of life, and increase physical and emotional participation in everyday activities. To accomplish these goals, pulmonary rehabilitation covers a range of nonpulmonary problems, including exercise deconditioning, relative social isolation, altered mood states (especially depression), muscle wasting, and weight loss. Patients with COPD at all stages of disease benefit from exercise training programs, improving with respect to both exercise tolerance and symptoms of dyspnea and fatigue (143) (Evidence A). Data suggest that these benefits can be sustained even after a single pulmonary rehabilitation program (144). Benefits have been reported from rehabilitation programs conducted in inpatient, outpatient, and home settings (147).
Ideally, pulmonary rehabilitation should involve several types of health professionals. A comprehensive pulmonary rehabilitation program includes exercise training, nutrition counseling, and education. Baseline and outcome assessments of each participant in a pulmonary rehabilitation program should be made to quantify individual gains and target areas for improvement and should include:
1. Detailed medical history and physical examination.
2. Measurement of spirometry before and after a bronchodilator drug.
3. Assessment of exercise capacity.
4. Measurement of health status and the impact of breathlessness.
5. Assessment of inspiratory and expiratory muscle strength and lower limb strength (e.g., quadriceps) in patients who suffer from muscle wasting (optional).
The first two assessments are important for establishing entry suitability and baseline status but are not used in outcome assessment. The last three assessments are essential baseline and outcome measures.
Oxygen therapy. The long-term administration of oxygen (> 15 h per day) to patients with chronic respiratory failure has been shown to increase survival (123, 124, 150, 151) (Evidence A). It can also have a beneficial impact on hemodynamics, hematologic characteristics, exercise capacity, lung mechanics, and mental state (152). Long-term oxygen therapy is generally introduced in Stage III: Severe COPD for patients who have: (1) PaO2 at or below 7.3 kPa (55 mm Hg) or SaO2 at or below 88%, with or without hypercapnia; or (2) PaO2 between 7.3 kPa (55 mm Hg) and 8.0 kPa (60 mm Hg) or SaO2 at or below 89%, if there is evidence of pulmonary hypertension, peripheral edema suggesting congestive heart failure, or polycythemia (hematocrit > 55%).
The goal of long-term oxygen therapy is to increase the baseline PaO2 to at least 8.0 kPa (60 mm Hg) or to produce SaO2 at least 90%, which will preserve vital organ function by ensuring an adequate delivery of oxygen. A decision about the use of long-term oxygen should be based on the waking PaO2 values. The prescription should always include the source of supplemental oxygen (gas or liquid), the method of delivery, duration of use, and the flow rate at rest, during exercise, and during sleep.
Ventilatory support. To date there is no convincing evidence that mechanical ventilatory support has a role in the routine management of stable COPD.
Surgical Treatments
Bullectomy. In carefully selected patients, this procedure is effective in reducing dyspnea and improving lung function (152) (Evidence C). A thoracic CT scan, arterial blood gas measurement, and comprehensive respiratory function tests are essential before making a decision regarding a patient's suitability for resection of a bulla.
Lung volume reduction surgery (LVRS). Although there are some encouraging reports (Evidence C), LVRS is still an unproven palliative surgical procedure (154, 155). Several large randomized studies are now underway to investigate the effectiveness and cost of LVRS in comparison to vigorous conventional therapy (156). Until the results of these studies are known, LVRS cannot be recommended for widespread use.
Lung transplantation. In appropriately selected patients with very advanced COPD, lung transplantation has been shown to improve quality of life and functional capacity (Evidence C) (157). Criteria for referral for lung transplantation include FEV1 < 35% predicted, PaO2 < 7.3 to 8.0 kPa (55 to 60 mm Hg), PaCO2 > 6.7 kPa (50 mm Hg), and secondary pulmonary hypertension (161).
Component 4: Manage Exacerbations
Key Points
2-agonists or
anticholinergics), theophylline, and systemic, preferably
oral, glucocorticosteroids are effective for treatments for
acute exacerbations of COPD (Evidence A).
|
|
|
2-agonists
are usually the preferred bronchodilators for treatment of
acute exacerbations of COPD (Evidence A) (81, 123, 124). If a
prompt response to these drugs does not occur, the addition of
an anticholinergic is recommended, even though evidence
concerning the effectiveness of this combination is rather controversial (186, 187). Despite its widespread clinical use, the
role of aminophylline in the treatment of COPD exacerbations remains controversial. Most studies of aminophylline
have demonstrated minor improvements in lung volumes but
also worsening of gas exchange and hypoxemia (188, 189). In
more severe exacerbations, addition of an oral or intravenous methylxanthine to the treatment can be considered. However,
close monitoring of serum theophylline is recommended to
avoid the side effects of these drugs (188, 190).
Glucocorticosteroids. Oral or intravenous glucocorticosteroids are recommended as an addition to bronchodilator therapy (plus eventually antibiotics and oxygen therapy) in the
hospital management of acute exacerbations of COPD (180-
182) (Evidence A). The exact dose that should be given is not
known, but high doses are associated with a significant risk of
side effects. Thirty to 40 mg of oral prednisolone daily for 10 to 14 d is a reasonable compromise between efficacy and
safety (Evidence D). Prolonged treatment does not result in a
greater efficacy and increases the risk of side effects.
Antibiotics. Antibiotics are only effective when patients
with worsening dyspnea and cough also have increased sputum volume and purulence (165). The choice of agents should
reflect local patterns of antibiotic sensitivity among S. pneumoniae, H. influenzae, and M. catarrhalis.
Ventilatory support. The primary objectives of mechanical
support in patients with acute exacerbations in Stage III: Severe COPD are to decrease mortality and morbidity and to relieve symptoms. Ventilatory support includes both noninvasive mechanical ventilation using either negative or positive
pressure devices, and invasive (conventional) mechanical ventilation by oro-/naso-tracheal tube or tracheostomy:
1. Noninvasive mechanical ventilation. NIPPV has been studied in many uncontrolled and five randomized controlled
trials in acute respiratory failure (193). The studies show
consistently positive results with success rates of 80 to 85%
(194). Taken together they provide evidence that NIPPV
increases pH, reduces PaCO2, reduces the severity of breathlessness in the first 4 h of treatment, and decreases the
length of hospital stay (Evidence A). More importantly,
mortality
or its surrogate, intubation rate
is reduced by
this intervention (195). However, NIPPV is not appropriate for all patients, as summarized in Table 14.
|
an advance directive or "living will"
makes these difficult decisions much easier to resolve.
|
|
|
| |
FUTURE RESEARCH |
|---|
|
|
|---|
A better understanding of molecular and cellular pathogenic mechanisms of COPD should lead to many new directions for both basic and clinical investigations. Improved methods for early detection, new approaches for interventions through targeted pharmacotherapy, possible means to identify the "susceptible" smoker, and more effective means of managing exacerbations are needed. Some research recommendations are provided; there are many additional avenues to explore.
1. Until there is a better understanding of the causal mechanisms of COPD, an absolutely rigid definition of COPD, and its relationship to other obstructive airway diseases, will remain controversial. Defining characteristics of COPD should be identified.
2. The stages of COPD and the disease course will vary from one patient to another. The GOLD Report describes four stages; their clinical utility needs to be evaluated.
3. Surrogate markers of inflammation, possibly derived from sputum (cells, mediators, enzymes) or exhaled condensates (lipid mediators, reactive oxygen species, cytokines), that may predict the clinical usefulness of new management and prevention strategies for COPD need to be developed.
4. Information is needed about the cellular and molecular mechanisms of inflammation in stable COPD and in exacerbations. Inflammatory responses in nonsmokers, ex-smokers, and smokers with and without COPD should be compared. The mechanisms responsible for the persistence of the inflammatory response in COPD should be investigated. Why inflammation in COPD is poorly responsive to glucocorticosteroids and what treatments other than glucocorticosteroids are effective in suppressing inflammation in COPD are research topics that could lead to new treatment modalities.
5. There is a pressing need to develop drugs that control symptoms and prevent the progression of COPD. Some progress has been made and there are several classes of drugs that are now in preclinical and clinical development for use in patients with COPD.
6. Standardized methods for tracking trends in COPD prevalence, morbidity, and mortality over time need to be developed so that countries can plan for future increases in the need for health care services in view of predicted increases in COPD. This need is especially urgent in developing countries with limited health care resources.
7. Longitudinal studies demonstrating the course of COPD are needed in a variety of populations exposed to various risk factors. Such studies would provide insight into the pathogenesis of COPD, identify additional genetic bases for COPD, and identify how genetic risk factors interact with environmental risk factors in specific patient populations. Factors that determine why some, but not all, smokers develop COPD need to be identified.
8. Data are needed on the use, cost, and relative distribution of medical and nonmedical resources for COPD, especially in countries where smoking and other risk factors are prevalent. These data are likely to have some impact on health policy and resource allocation decisions. As options for treating COPD grow, more research will be needed to help guide health care providers and health budget managers regarding the most efficient and effective ways of managing this disease. Methods and strategies for implementation of COPD management programs in developing countries will require special attention.
9. While spirometry is recommended to assess and monitor COPD, other measures need to be developed and evaluated in clinical practice. Reproducible and inexpensive exercise-testing methodologies (e.g., stair-climbing tests) suitable for use in developing countries need to be evaluated and their use encouraged. Spirometers need to be developed that can ensure economical and accurate performance when a relatively untrained operator administers the test.
10. Because COPD is not fully reversible (with current therapies) and slowly progressive, it will become ever more important to identify early cases as more effective therapies emerge. Consensus on standard methods for detection and definition of early disease need to be developed. Data to show whether or not screening spirometry is effective in directing management decisions in COPD outcomes are required.
11. Primary prevention of COPD is one of the major objectives of GOLD. Investigations into the most cost-effective ways to reduce the prevalence of tobacco smoking in the general population and more specifically in young people are very much needed. Strategies to prevent people from starting to smoke and methods for smoking cessation require constant evaluation and improvement. Research is required to gauge the impact and reduce the risk from growing air pollution, urbanization, recurrent childhood infections, occupational exposures, and use of local cigarette equivalents. Programs designed to reduce exposure to biomass fuel in countries where this is used for cooking and domestic heating should be explored in an effort to reduce exposure and improve ventilation in the homes.
12. The specific components of effective education for patients with COPD need to be determined. It is not known, for example, whether patients with COPD should be given an individual management plan, or whether these plans are effective in reducing health care costs or improving the outcomes of exacerbations. Developing and evaluating effective tools for physician education concerning prevention, diagnosis, and management of COPD will be important in view of the increasing public health problem presented by COPD.
13. Studies are needed to determine whether education is an essential component of pulmonary rehabilitation. The cost-effectiveness of rehabilitation programs has not been assessed and there is a need to assess the feasibility, resource utilization, and health outcomes of rehabilitation programs that can be delivered outside the major teaching hospital setting. Criteria for selecting individuals for rehabilitation should be evaluated, along with methods to modify programs to suit the needs of individual patients.
14. Collecting and evaluating data to set levels of severity for COPD exacerbations would stimulate standardization of this outcome measure that is so frequently used in clinical trials. Better data on outcomes of COPD exacerbations would allow physicians to provide better advice to patients on possible outcomes and appropriateness of various types of treatment. Further exploration of the ethical principles of life support and greater insights into the behavioral influences that inhibit discussion of end-of-life issues are needed, along with studies to define the needs of patients with end-stage COPD.
| |
Consultant Reviewers |
|---|
|
|
|---|
Individuals Sherwood Burge (UK)
Moira Chan-Yeung (Hong Kong) James Donohue (US) Nicholas J. Gross (US) Helgo Magnussen (Germany) Donald Mahler (US) Jean-Francois Muir (France) Mrigrendra Pandey (India) Peter Pare (Canada) Thomas Petty (US) Michael Plit (South Africa) Sri Ram (US) Harold Rea (New Zealand) Andrea Rossi (Italy) Maureen Rutten-van Molken (The Netherlands) Marina Saetta (Italy) Raj Singh (India) Frank Speizer (US) Robert Stockley (UK) Donald Tashkin, M.D. (US) Ian Town (New Zealand) Paul Vermeire (Belgium) Gregory Wagner (US) Scott Weiss, M.D. (US) Miel Wouters (The Netherlands) Jan Zielinski (Poland)Organizations
American Thoracic Society
Bart Celli
William Martin
Austrian Respiratory Society
Friedriech Kummer
Arab Respiratory Society
Salem El Sayed
Thoracic Society of Australia and New Zealand
Alastair Stewart
David McKenzie
Peter Frith
Australian Lung Foundation
Robert Edwards
Belgian Society of Pneumology
Marc Decramer
Jean-Claude Yernault
British Thoracic Society
Neil Pride
Canadian Thoracic Society
Louis-Philippe Boulet
Kenneth Chapman
Chinese Respiratory Society
Nan-San Zhong
Yuanjue Zhu
Croatian Respiratory Society
Neven Rakusic
Davor Plavec
Czech Thoracic Society
Stanislav Kos
Jaromir Musil
Vladimir Vondra
European Respiratory Society
Marc Decramer (Belgium)
French speaking Pneumological Society
Michel Fournier
Thomas Similovski
Hungarian Respiratory Society
Pal Magyar
Japanese Respiratory Society
Yoshinosuke Fukuchi
Latin American Thoracic Society
Juan Figureoa (Argentina)
Maria Christina Machado (Brasil)
Ilma Paschoal (Brasil)
Jose Jardim (Brasil)
Gisele Borzone (Chile)
Orlando Diaz (Chile)
Patricio Gonzales (Chile)
Carmen Lisboa (Chile)
Rogelio Perez Padilla (Mexico)
Jorge Rodriguez De Marco (Uruguay)
Maria Victorina Lopez (Uruguay)
Roberto Lopez (Uruguay)
Malaysian Thoracic Society
Zin Zainudin
Norwegian Thoracic Society
Amund Gulsvik
Ernst Omenaas
Polish Phthisiopneumonological Society
Michal Pirozynski
Romanian Society of Pulmonary Diseases
Traian Mihaescu
Sabina Antoniu
Singapore Thoracic Society
Alan Ng Wei Keong
Slovakian Pneumological and Phthisiological Society
Ladislav Chovan
Slovenian Respiratory Society
Stanislav Suskovic
South African Thoracic Society
James Joubert
Spanish Society of Pneumology
Teodoro Montemayor Rubio
Victor Sobradillo
Swedish Society for Chest Physicians
Kjell Larsson
Sven Larsson
Claes-Goran Lofdahl
Swiss Pulmonary Society
Philippe Leuenberger
Erich Russi
Thoracic Society of Thailand
Ploysongsang Youngyudh
Vietnam Asthma-Allergology and Clinical Immunology Association
Nguyen Nang An
| |
Footnotes |
|---|
Correspondence and requests for reprints should be addressed to Romain Pauwels, Department of Respiratory Diseases, University Hospital, De Pintelaan 185, B9000 Ghent, Belgium. E-mail: romain.pauwels{at}rug.ac.be
(Received in original form January 10, 2001).
List of participants (GOLD Scientific Committee): Nicholas Anthonisen, Winnipeg, Canada; William C. Bailey, Birmingham, US; Peter J. Barnes, London, UK; Tim Clark, London, UK; Leonardo Fabbri, Modena, Italy; Yoshinosuke Fukuchi, Tokyo, Japan; Lawrence Grouse, Seattle, US; James C. Hogg, Vancouver, Canada; Dirkje S. Postma, Groningen, the Netherlands; Klaus F. Rabe, Leiden, the Netherlands; Scott D. Ramsey, Seattle, US; Stephen I. Rennard, Omaha, US; Roberto Rodriguez-Roisin, Barcelona, Spain; Nikos Siafakas, Heraklion, Greece; Sean D. Sullivan, Seattle, US; Wan-Cheng Tan, Singapore; Claude Lenfant, NHLBI, Bethesda, US; Nikolai Khaltaev, WHO, Geneva, Switzerland.
Acknowledgments:
The authors thank Sarah DeWeerdt for editorial assistance.
| |
References |
|---|
|
|
|---|
1. National Heart, Lung, and Blood Institute. Morbidity & Mortality: Chartbook on Cardiovascular, Lung, and Blood Diseases. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda, MD. 1998. Available from: URL: http://www.nhlbi.nih.gov/nhlbi/seiin/other/cht-book/htm.
2.
Murray CJL,
Lopez AD.
Evidence-based health policy
lessons from
the Global Burden of Disease Study.
Science
1996;
274:
740-743
3. World Health Report. World Health Organization, Geneva. 2000. Available from URL: http://www.who.int/whr/2000/en/statistics.htm.
4.
Hill AT,
Bayley D,
Stockley RA.
The interrelationship of sputum inflammatory markers in patients with chronic bronchitis.
Am J Respir
Crit Care Med
1999;
160:
893-898
5. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153: 530-534 [Abstract].
6. Pesci A, Balbi B, Majori M, Cacciani G, Bertacco S, Alciato P, Donner CF. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Respir J 1998; 12: 380-386 [Abstract].
7.
Yamamoto C,
Yoneda T,
Yoshikawa M,
Fu A,
Tokuyama T,
Tsukaguchi K,
Narita N.
Airway inflammation in COPD assessed by sputum
levels of interleukin-8.
Chest
1997;
112:
505-510
8. Mueller R, Chanez P, Campbell AM, Bousquet J, Heusser C, Bullock GR. Different cytokine patterns in bronchial biopsies in asthma and chronic bronchitis. Respir Med 1996; 90: 79-85 [Medline].
9. Mullen JB, Wright JL, Wiggs BR, Pare PD, Hogg JC. Reassessment of inflammation of airways in chronic bronchitis. Br Med J (Clin Res Ed) 1985; 291: 1235-1239 .
10. Cosio M, Ghezzo H, Hogg JC, Corbin R, Loveland M, Dosman J, Macklem PT. The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med 1978; 298: 1277-1281 [Abstract].
11. Niewoehner DE, Kleinerman J, Rice DB. Pathologic changes in the peripheral airways of young cigarette smokers. N Engl J Med 1974; 291: 755-758 .
12. Wright JL, Lawson LM, Pare PD, Wiggs BJ, Kennedy S, Hogg JC. Morphology of peripheral airways in current smokers and ex-smokers. Am Rev Respir Dis 1983; 127: 474-477 [Medline].
13. Ollerenshaw SL, Woolcock AJ. Characteristics of the inflammation in biopsies from large airways of subjects with asthma and subjects with chronic airflow limitation. Am Rev Respir Dis 1992; 145: 922-927 [Medline].
14. Hunninghake GW, Crystal RG. Cigarette smoking and lung destruction: accumulation of neutrophils in the lungs of cigarette smokers. Am Rev Respir Dis 1983; 128: 833-838 [Medline].
15. Li XY, Brown D, Smith S, MacNee W, Donaldson K. Short-term inflammatory responses following intratracheal instillation of fine and ultrafine carbon black in rats. Inhal Toxicol 1999; 11: 709-731 . [Medline]
16. Monn C, Becker S. Cytotoxicity and induction of proinflammatory cytokines from human monocytes exposed to fine (PM2.5) and coarse particles (PM10-2.5) in outdoor and indoor air. Toxicol Appl Pharmacol 1999; 155: 245-252 [Medline].
17.
Salvi S,
Blomberg A,
Rudell B,
Kelly F,
Sandstrom T,
Holgate ST,
Frew A.
Acute inflammatory responses in the airways and peripheral
blood after short-term exposure to diesel exhaust in healthy human
volunteers.
Am J Respir Crit Care Med
1999;
159:
702-709
18.
Von Essen SG,
O'Neill DP,
McGranaghan S,
Olenchock SA,
Rennard SI.
Neutrophilic respiratory tract inflammation and peripheral blood
neutrophilia after grain sorghum dust extract challenge.
Chest
1995;
108:
1425-1433
19. Von Essen SG, Robbins RA, Thompson AB, Ertl RF, Linder J, Rennard SI. Mechanisms of neutrophil recruitment to the lung by grain dust exposure [published erratum appears in Am Rev Respir Dis 1989;139:1065]. Am Rev Respir Dis 1988; 138: 921-927 [Medline].
20. O'Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997; 155: 852-857 [Abstract].
21. Saetta M, Di Stefano A, Maestrelli P, Ferraresso A, Drigo R, Potena A, Ciaccia A, Fabbri LM. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis 1993; 147: 301-306 [Medline].
22.
Saetta M,
Di Stefano A,
Turato G,
Facchini FM,
Corbino L,
Mapp CE,
Maestrelli P,
Ciaccia A,
Fabbri LM.
CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med
1998;
157:
822-826
23. Leopold JG, Goeff J. Centrilobular form of hypertrophic emphysema and its relation to chronic bronchitis. Thorax 1957; 12: 219-235 .
24. McLean KA. Pathogenesis of pulmonary emphysema. Am J Med 1958; 25: 62-74 .
25.
Repine JE,
Bast A,
Lankhorst I.
Oxidative stress in chronic obstructive
pulmonary disease. Oxidative Stress Study Group.
Am J Respir Crit
Care Med
1997;
156:
341-357
26. Wright JL, Lawson L, Pare PD, Hooper RO, Peretz DI, Nelems JM, Schulzer M, Hogg JC. The structure and function of the pulmonary vasculature in mild chronic obstructive pulmonary disease: the effect of oxygen and exercise. Am Rev Respir Dis 1983; 128: 702-707 [Medline].
27.
Peinado VI,
Barbera JA,
Abate P,
Ramirez J,
Roca J,
Santos S,
Rodriguez-Roisin R.
Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease.
Am J Respir Crit Care Med
1999;
159:
1605-1611
28. Riley DJ, Thakker-Varia S, Poiani GJ, Tozzi CA. Vascular remodeling. In: RG Crystal, JB West, PJ Barnes, ER Weibel, editors. The lung: scientific foundations, 2nd ed. Philadelphia: Lippincott-Raven; 1997. p. 1589-1597.
29. MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part Two. Am J Respir Crit Care Med 1994; 150: 1158-1168 [Medline].
30. Pride NB, Vermeire P, Allegra L. Diagnostic labels applied to model case histories of chronic airflow obstruction: responses to a questionnaire in 11 North American and western European countries. Eur Respir J 1989; 2: 702-709 [Abstract].
31.
Mannino DM,
Brown C,
Giovino GA.
Obstructive lung disease deaths
in the United States from 1979 through 1993: an analysis using multiple-cause mortality data.
Am J Respir Crit Care Med
1997;
156:
814-818
32. Murray CJL, Lopez AD, editors. 1996. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Harvard University Press, Cambridge, MA.
33. Buist AS, Vollmer WM. Smoking and other risk factors. In: JF Murray, JA Nadel, editors. Textbook of respiratory medicine. WB Saunders; Philadelphia: 1994. p. 1259-1287.
34. Thom TJ. International comparisons in COPD mortality. Am Rev Respir Dis 1989; 140: S27-34 [Medline].
35. Xu X, Weiss ST, Rijcken B, Schouten JP. Smoking, changes in smoking habits, and rate of decline in FEV1: new insight into gender differences. Eur Respir J 1994; 7: 1056-1061 [Abstract].
36. Feinleib M, Rosenberg HM, Collins JG, Delozier JE, Pokras R, Chevarley FM. Trends in COPD morbidity and mortality in the United States. Am Rev Respir Dis 1989; 140: S9-18 [Medline].
37. U.S. Centers for Disease Control and Prevention: Vital and Health Statistics: Current Estimates from the National Health Interview Survey. Department of Health and Human Service, Public Health Service. 1995. Publication No 96-1527.
38.
Anthonisen NR,
Connett JE,
Kiley JP,
Altose MD,
Bailey WC,
Buist AS,
Conway WA Jr,,
Enright PL,
Kanner RE,
O'Hara P, et al
.
Effects
of smoking intervention and the use of an inhaled anticholinergic
bronchodilator on the rate of decline of FEV1. The Lung Health
Study.
JAMA
1994;
272:
1497-1505
39. Laurell CB, Eriksson S. The electrophoretic alpha-1 globulin pattern of serum in alpha-1 antitrypsin deficiency. Scand J Clin Lab Invest 1963; 15: 132-140 .
40. Hubbard RC, Crystal RG. Antiproteases. In: RB Crystal, JB West, PJ Barnes, NS Cherniack, ER Weibel, editors. The lung: scientific foundations. New York: Raven Press; 1991. p. 1775-1787.
41. McElvaney NG, Crystal RG. Inherited susceptibility of the lung to proteolytic injury. In: RG Crystal, JB West, ER Weibel, PJ Barnes, editors. The Lung: Scientific Foundations, 2nd ed. Philadelphia: Lippincott-Raven; 1997. p. 2537-2553.
42. Orie NGM, Sluiter HJ, De Vreis K, Tammerling K, Wikop J. The host factor in bronchitis. In: NGM Orie, HG Sluiter, editors. Bronchitis, An International Symposium. Assen, Netherlands: Royal Vangorcum; 1961. p. 43-59.
43.
Hagstrom B,
Nyberg P,
Nilsson PM.
Asthma in adult life
is there an
association with birth weight?
Scand J Prim Health Care
1998;
16:
117-120
[Medline].
44. Svanes C, Omenaas E, Heuch JM, Irgens LM, Gulsvik A. Birth characteristics and asthma symptoms in young adults: results from a population-based cohort study in Norway. Eur Respir J 1998; 12: 1366-1370 [Abstract].
45. Todisco T, de Benedictis FM, Iannacci L, Baglioni S, Eslami A, Todisco E, Dottorini M. Mild prematurity and respiratory functions. Eur J Pediatr 1993; 152: 55-58 [Medline].
46. Stein CE, Kumaran K, Fall CH, Shaheen SO, Osmond C, Barker DJ. Relation of fetal growth to adult lung function in South India. Thorax 1997; 52: 895-899 [Abstract].
47.
Morgan WJ.
Maternal smoking and infant lung function: further evidence
for an in utero effect.
Am J Respir Crit Care Med
1998;
158:
689-690
48. Tager IB, Segal MR, Speizer FE, Weiss ST. The natural history of forced expiratory volumes: effect of cigarette smoking and respiratory symptoms. Am Rev Respir Dis 1988; 138: 837-849 [Medline].
49. U.S. Surgeon General. The Health Consequences of Smoking: Chronic Obstructive Pulmonary Disease. U.S. Department of Health and Human Services, Washington, DC. 1984. Publication No. 84-50205.
50. Leuenberger P, Schwartz J, Ackermann-Liebrich U, Blaser K, Bolognini G, Bongard JP, Brandli O, Braun P, Bron C, Brutsche M, et al . Passive smoking exposure in adults and chronic respiratory symptoms (SAPALDIA Study). Swiss Study on Air Pollution and Lung Diseases in Adults, SAPALDIA Team. Am J Respir Crit Care Med 1994; 150: 1222-1228 [Abstract].
51. Dayal HH, Khuder S, Sharrar R, Trieff N. Passive smoking in obstructive respiratory disease in an industrialized urban population. Environ Res 1994; 65: 161-171 [Medline].
52.
Holt PG.
Immune and inflammatory function in cigarette smokers.
Thorax
1987;
42:
241-249
53.
Kauffmann F,
Drouet D,
Lellouch J,
Brille D.
Twelve years spirometric
changes among Paris area workers.
Int J Epidemiol
1979;
8:
201-212
54. Niewoehner DE. Anatomic and pathophysiological correlations in COPD. In GL Baum, JD Crapo, BR Celli, JB Karlinsky, editors. Textbook of Pulmonary Diseases. Philadelphia: Lippincott-Raven; 1998. p. 823-842.
55. Chen JC, Mannino MD. Worldwide epidemiology of chronic obstructive pulmonary disease. Current Opin Pulmon Med 1999; 5: 93-99 . [Medline]
56. Perez-Padilla R, Regalado U, Vedal S, Pare P, Chapela R, Sansores R. Exposure to biomass smoke and chronic airway disease in Mexican women. Am J Respir Crit Care Med 1996; 154: 701-706 [Abstract].
57. Dossing M, Khan Jal-Rabiah F. Risk factors for chronic obstructive lung disease in Saudi Arabia. Respir Med 1994;88:519-522.
58.
Behera D,
Jindal SK.
Respiratory symptoms in Indian women using
domestic cooking fuels.
Chest
1991;
100:
385-388
59. Amoli K. Bronchopulmonary disease in Iranian housewives chronically exposed to indoor smoke. Eur Respir J 1998; 11: 659-663 [Abstract].
60.
Dennis R,
Maldonado D,
Norman S,
Baena E,
Martinez G.
Woodsmoke exposure and risk for obstructive airways disease among
women.
Chest
1996;
109:
115-119
61.
Pandey MR.
Prevalence of chronic bronchitis in a rural community of
the Hill Region of Nepal.
Thorax
1984;
39:
331-336
62.
Pandey MR.
Domestic smoke pollution and chronic bronchitis in a rural community of the Hill Region of Nepal.
Thorax
1984;
39:
337-339
63. Samet JM, Marbury M, Spengler J. Health effects and sources of indoor air pollution. Am Rev Respir Dis 1987; 136: 1486-1508 [Medline].
64. Tao X, Hong CJ, Yu S, Chen B, Zhu H, Yang M. Priority among air pollution factors for preventing chronic obstructive pulmonary disease in Shanghai. Sci Total Environ 1992; 127: 57-67 [Medline].
65. Prescott E, Lange P, Vestbo J. Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. Eur Respir J 1999; 13: 1109-1114 [Abstract].
66. Strachan DP. Epidemiology: A British perspective. In: PMA Calverley, NB Pride, editors. Chronic obstructive pulmonary disease. London: Chapman and Hall; 1995. p. 47-67.
67. Georgopoulas D, Anthonisen NR. Symptoms and signs of COPD. In: NS Cherniack, editor. Chronic obstructive pulmonary disease. Toronto: WB Saunders; 1991. p. 357-363.
68. Loveridge B, West P, Kryger MH, Anthonisen NR. Alteration in breathing pattern with progression of chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 134: 930-934 [Medline].
69.
Kesten S,
Chapman KR.
Physician perceptions and management of
COPD.
Chest
1993;
104:
254-258
70. Reis AL. Response to bronchodilators. In: Clausen J, editor. Pulmonary function testing: guidelines and controversies. New York: Academic Press; 1982.
71. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991; 144:1202-1218.
72. Wilson DH, Wakefield MA, Steven ID, Rohrsheim RA, Esterman AJ, Graham NM. "Sick of Smoking": evaluation of a targeted minimal smoking cessation intervention in general practice. Med J Aust 1990; 152: 518-521 [Medline].
73.
Britton J,
Knox A.
Helping people to stop smoking: the new smoking
cessation guidelines.
Thorax
1999;
54:
1-2
74. Fiore MC, Bailey WC, Cohen SJ. Smoking Cessation: Information for Specialists. U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research and Centers for Disease Control and Prevention, Rockville, MD. 1996. AHCPR Publication No. 96-0694.
75. The tobacco use and dependence clinical practice guideline panel, staff, and consortium representatives. A clinical practice guideline for treating tobacco use and dependence. JAMA 2000;28:3244-3254.
76. American Medical Association. Guidelines for the Diagnosis and Treatment of Nicotine Dependence: How to Help Patients Stop Smoking. American Medical Association, Washington DC. 1994.
77. Glynn TJ, Manley MW, Pechacek TF. Physician-initiated smoking cessation program: the National Cancer Institute trials. Prog Clin Biol Res 1990; 339: 11-25 [Medline].
78. Glynn TJ, Manley MW. How to Help Your Patients Stop Smoking. A National Cancer Institute Manual for Physicians. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, Bethesda, MD. 1990. NIH Publication No. 90-3064.
79.
Fiore MC,
Smith SS,
Jorenby DE,
Baker TB.
The effectiveness of the
nicotine patch for smoking cessation: a meta-analysis.
JAMA
1994;
271:
1940-1947
80.
Lancaster T,
Stead L,
Silagy C,
Sowden A.
Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library.
BMJ
2000;
321:
355-358
81. The COPD Guidelines Group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997;52(Suppl 5):S1-28.
82. Samet J, Utell MJ. Ambient air pollution. In: L Rosenstock, M Cullen, editors. Textbook of occupational and environmental medicine. Philadelphia: WB Saunders; 1994. p. 53-60.
83.
Ries AL,
Kaplan RM,
Limberg TM,
Prewitt LM.
Effects of pulmonary
rehabilitation on physiologic and psychosocial outcomes in patients
with chronic obstructive pulmonary disease.
Ann Intern Med
1995;
122:
823-832
84. Janelli LM, Scherer YK, Schmieder LE. Can a pulmonary health teaching program alter patients' ability to cope with COPD? Rehabil Nurs 1991; 16: 199-202 [Medline].
85. Ashikaga T, Vacek PM, Lewis SO. Evaluation of a community-based education program for individuals with chronic obstructive pulmonary disease. J Rehabil 1980; 46: 23-27 [Medline].
86. Toshima MT, Kaplan RM, Ries AL. Experimental evaluation of rehabilitation in chronic obstructive pulmonary disease: short-term effects on exercise endurance and health status. Health Psychol 1990; 9: 237-252 [Medline].
87. Celli BR. Pulmonary rehabilitation in patients with COPD. Am J Respir Crit Care Med 1995; 152: 861-864 [Abstract].
88. Heffner JE, Fahy B, Hilling L, Barbieri C. Outcomes of advance directive education of pulmonary rehabilitation patients. Am J Respir Crit Care Med 1997; 155: 1055-1059 [Abstract].
89. Stewart MA. Effective physician-patient communication and health outcomes: a review. CMAJ 1995; 152: 1423-1433 . [Abstract]
90. Clark NM, Nothwehr F, Gong M, Evans D, Maiman LA, Hurwitz ME, Roloff D, Mellins RB. Physician-patient partnership in managing chronic illness. Acad Med 1995; 70: 957-959 [Medline].
91.
Pauwels RA,
Lofdahl CG,
Laitinen LA,
Schouten JP,
Postma DS,
Pride NB,
Ohlsson SV.
Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease
who continue smoking. European Respiratory Society Study on
Chronic Obstructive Pulmonary Disease.
N Engl J Med
1999;
340:
1948-1953
92. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819-1823 [Medline].
93.
Burge PS,
Calverley PM,
Jones PW,
Spencer S,
Anderson JA,
Maslen TK.
Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.
BMJ
2000;
320:
1297-1303
94. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease: N Engl J Med 2000;343:1902-1909.
95. Vathenen AS, Britton JR, Ebden P, Cookson JB, Wharrad HJ, Tattersfield AE. High-dose inhaled albuterol in severe chronic airflow limitation. Am Rev Respir Dis 1988; 138: 850-855 [Medline].
96. Gross NJ, Petty TL, Friedman M, Skorodin MS, Silvers GW, Donohue JF. Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease: A three-center study. Am Rev Respir Dis 1989; 139: 1188-1191 [Medline].
97. Chrystyn H, Mulley BA, Peake MD. Dose response relation to oral theophylline in severe chronic obstructive airways disease. BMJ 1988; 297: 1506-1510 .
98. Higgins BG, Powell RM, Cooper S, Tattersfield AE. Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis. Eur Respir J 1991; 4: 415-420 [Abstract].
99.
Jenkins SC,
Heaton RW,
Fulton TJ,
Moxham J.
Comparison of domiciliary nebulized salbutamol and salbutamol from a metered-dose inhaler in stable chronic airflow limitation.
Chest
1987;
91:
804-807
100.
Ikeda A,
Nishimura K,
Koyama H,
Tsukino M,
Mishima M,
Izumi T.
Dose response study of ipratropium bromide aerosol on maximum
exercise performance in stable patients with chronic obstructive pulmonary disease.
Thorax
1996;
51:
48-53
101. Guyatt GH, Townsend M, Pugsley SO, Keller JL, Short HD, Taylor DW, Newhouse MT. Bronchodilators in chronic air-flow limitation: effects on airway function, exercise capacity, and quality of life. Am Rev Respir Dis 1987; 135: 1069-1074 [Medline].
102. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283-1289 [Abstract].
103.
Mahler DA,
Donohue JF,
Barbee RA,
Goldman MD,
Gross NJ,
Wisniewski ME,
Yancey SW,
Zakes BA,
Rickard KA,
Anderson WH.
Efficacy of salmeterol xinafoate in the treatment of COPD.
Chest
1999;
115:
957-965
104. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial. Chest 1994;105:1411-1419.
105. The COMBIVENT Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997;112:1514-1521.
106. Gross N, Tashkin D, Miller R, Oren J, Coleman W, Linberg S. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group. Respiration 1998; 65: 354-362 [Medline].
107.
Ulrik CS.
Efficacy of inhaled salmeterol in the management of smokers
with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study.
Thorax
1995;
50:
750-754
108. Taylor DR, Buick B, Kinney C, Lowry RC, McDevitt DG. The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. Am Rev Respir Dis 1985; 131: 747-751 [Medline].
109. van Noord JA, de Munck DR, Bantje TA, Hop WC, Akveld ML, Bommer AM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000; 15: 878-885 [Abstract].
110. Murciano D, Auclair MH, Pariente R, Aubier M. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med 1989; 320: 1521-1525 [Abstract].
111. O'Driscoll BR, Kay EA, Taylor RJ, Weatherby H, Chetty MC, Bernstein A. A long-term prospective assessment of home nebulizer treatment. Respir Med 1992; 86: 317-325 [Medline].
112. Tashkin DP, Bleecker E, Braun S, Campbell S, DeGraff AC Jr,, Hudgel DW, Boyars MC, Sahn S. Results of a multicenter study of nebulized inhalant bronchodilator solutions. Am J Med 1996; 100: 62S-69 [Medline].
113. Senderovitz T, Vestbo J, Frandsen J, Maltbaek N, Norgaard M, Nielsen C, Kampmann JP. Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. The Danish Society of Respiratory Medicine. Respir Med 1999; 93: 715-718 [Medline].
114.
Rice KL,
Rubins JB,
Lebahn F,
Parenti CM,
Duane PG,
Kuskowski M,
Joseph AM,
Niewoehner DE.
Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial.
Am J Respir
Crit Care Med
2000;
162:
174-178
115. Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 1994; 150: 11-16 [Abstract].
116. Decramer M, Stas KJ. Corticosteroid-induced myopathy involving respiratory muscles in patients with chronic obstructive pulmonary disease or asthma. Am Rev Respir Dis 1992; 146: 800-802 [Medline].
117.
Nichol KL,
Margolis KL,
Wuorenma J,
Von Sternberg T.
The efficacy
and cost effectiveness of vaccination against influenza among elderly
persons living in the community.
N Engl J Med
1994;
331:
778-784
118. Edwards KM, Dupont WD, Westrich MK, Plummer WD Jr,, Palmer PS, Wright PF. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994; 169: 68-76 [Medline].
119. Simberkoff MS, Cross AP, Al-Ibrahim M, Baltch AL, Geiseler PJ, Nadler J, Richmond AS, Smith RP, Schiffman G, Shepard DS, et al . Efficacy of pneumococcal vaccine in high-risk patients: results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 315: 1318-1327 [Abstract].
120. Williams JH Jr,, Moser KM. Pneumococcal vaccine and patients with chronic lung disease. Ann Intern Med 1986; 104: 106-109 .
121.
Davis AL,
Aranda CP,
Schiffman G,
Christianson LC.
Pneumococcal
infection and immunologic response to pneumococcal vaccine in
chronic obstructive pulmonary disease: a pilot study.
Chest
1987;
92:
204-212
122. Isada CM, Stoller JK. Chronic bronchitis: the role of antibiotics. In: MS Niederman, GA Sarosi, J Glassroth, editors. Respiratory infections: a scientific basis for management. London: WB Saunders; 1994. p. 621-633.
123. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S77-121.
124. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, Yernault JC, Decramer M, Higenbottam T, Postma DS, et al . Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995; 8: 1398-1420 [Medline].
125. Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2000;2:Available from URL www.update-software.com or http://www.updatusa. com.
126. Hansen NC, Skriver A, Brorsen-Riis L, Balslov S, Evald T, Maltbaek N, Gunnersen G, Garsdal P, Sander P, Pedersen JZ, et al . Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med 1994; 88: 531-535 [Medline].
127. British Thoracic Society Research Committee. Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. Thorax 1985;40:832-835.
128. Boman G, Backer U, Larsson S, Melander B, Wahlander L. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis 1983; 64: 405-415 [Medline].
129. Rasmussen JB, Glennow C. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis. Eur Respir J 1988; 1: 351-355 [Abstract].
130.
Collet JP,
Shapiro P,
Ernst P,
Renzi T,
Ducruet T,
Robinson A.
Effects
of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The
PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant.
Am J
Respir Crit Care Med
1997;
156:
1719-1724
131.
Anthonisen NR.
OM-8BV for COPD.
Am J Respir Crit Care Med
1997;
156:
1713-1714
132.
Irwin RS,
Boulet LP,
Cloutier MM,
Fuller R,
Gold PM,
Hoffstein V,
Ing AJ,
McCool FD,
O'Byrne P,
Poe RH,
Prakash UB,
Pratter MR,
Rubin BK.
Managing cough as a defense mechanism and as a symptom: a consensus panel report of the American College of Chest Physicians.
Chest
1998;
114:
133S-181S
133. Barbera JA, Roger N, Roca J, Rovira I, Higenbottam TW, Rodriguez-Roisin R. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet 1996; 347: 436-440 [Medline].
134. Jones AT, Evans TW. NO: COPD and beyond. Thorax 1997;52(Suppl 3):S16-21.
135. Bardsley PA, Howard P, DeBacker W, Vermeire P, Mairesse M, Ledent C, Radermecker M, Bury T, Ansquer J. Two years treatment with almitrine bismesylate in patients with hypoxic chronic obstructive airways disease. Eur Respir J 1991; 4: 308-310 [Abstract].
136. Watanabe S, Kanner RE, Cutillo AG, Menlove RL, Bachand RT Jr,, Szalkowski MB, Renzetti AD Jr.. Long-term effect of almitrine bismesylate in patients with hypoxemic chronic obstructive pulmonary disease. Am Rev Respir Dis 1989; 140: 1269-1273 [Medline].
137.
Winkelmann BR,
Kullmer TH,
Kneissl DG,
Trenk D,
Kronenberger H.
Low-dose almitrine bismesylate in the treatment of hypoxemia
due to chronic obstructive pulmonary disease.
Chest
1994;
105:
1383-1391
138. Eiser N, Denman WT, West C, Luce P. Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the "pink puffer" syndrome. Eur Respir J 1991; 4: 926-931 [Abstract].
139.
Young IH,
Daviskas E,
Keena VA.
Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease.
Thorax
1989;
44:
387-390
140. Rice KL, Kronenberg RS, Hedemark LL, Niewoehner DE. Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Br J Dis Chest 1987; 81: 287-292 [Medline].
141. Woodcock AA, Gross ER, Gellert A, Shah S, Johnson M, Geddes DM. Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. N Engl J Med 1981; 305: 1611-1616 [Abstract].
142.
Poole PJ,
Veale AG,
Black PN.
The effect of sustained-release morphine
on breathlessness and quality of life in severe chronic obstructive pulmonary disease.
Am J Respir Crit Care Med
1998;
157:
1877-1880
143.
Berry MJ,
Rejeski WJ,
Adair NE,
Zaccaro D.
Exercise rehabilitation
and chronic obstructive pulmonary disease stage.
Am J Respir Crit
Care Med
1999;
160:
1248-1253
144. Foglio K, Bianchi L, Bruletti G, Battista L, Pagani M, Ambrosino N. Long-term effectiveness of pulmonary rehabilitation in patients with chronic airway obstruction. Eur Respir J 1999; 13: 125-132 [Abstract].
145. Young P, Dewse M, Fergusson W, Kolbe J. Improvements in outcomes for chronic obstructive pulmonary disease (COPD) attributable to a hospital-based respiratory rehabilitation programme. Aust N Z J Med 1999; 29: 59-65 [Medline].
146. Griffiths TL, Burr ML, Campbell IA, Lewis-Jenkins V, Mullins J, Shiels K, Turner-Lawlor PJ, Payne N, Newcombe RG, Ionescu AA, Thomas J, Tunbridge J, Lonescu AA. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet 2000; 355: 362-368 [Medline].
147. Goldstein RS, Gort EH, Stubbing D, Avendano MA, Guyatt GH. Randomised controlled trial of respiratory rehabilitation. Lancet 1994; 344: 1394-1397 [Medline].
148. Wijkstra PJ, Van Altena R, Kraan J, Otten V, Postma DS, Koeter GH. Quality of life in patients with chronic obstructive pulmonary disease improves after rehabilitation at home. Eur Respir J 1994; 7: 269-273 [Abstract].
149.
McGavin CR,
Gupta SP,
Lloyd EL,
McHardy GJ.
Physical rehabilitation for the chronic bronchitic: results of a controlled trial of exercises in the home.
Thorax
1977;
32:
307-311
150. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980;93:391-398.
151. Report of the Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981;1:681-686.
152.
Tarpy SP,
Celli BR.
Long-term oxygen therapy.
N Engl J Med
1995;
333:
710-714
153. Mehran RJ, Deslauriers J. Indications for surgery and patient work-up for bullectomy. Chest Surg Clin North Am 1995; 5: 717-734 [Medline].
154. Benditt JO, Albert RK. Surgical options for patients with advanced emphysema. Clin Chest Med 1997; 18: 577-593 [Medline].
155.
Geddes D,
Davies M,
Koyama H,
Hansell D,
Pastorino U,
Pepper J,
Agent P,
Cullinan P,
MacNeill SJ,
Goldstraw P.
Effect of lung-volume-reduction surgery in patients with severe emphysema.
N Engl J
Med
2000;
343:
239-245
156. The National Emphysema Treatment Trial Research Group. Rationale and design of The National Emphysema Treatment Trial: a prospective randomized trial of lung volume reduction surgery. Chest 1999; 116:1750-1761.
157. Trulock EP. Lung transplantation. Am J Respir Crit Care Med 1997; 155: 789-818 [Medline].
158. Theodore J, Lewiston N. Lung transplantation comes of age. N Engl J Med 1990; 322: 772-774 [Medline].
159.
Hosenpud JD,
Bennett LE,
Keck BM,
Fiol B,
Boucek MM,
Novick RJ.
The Registry of the International Society for Heart and Lung Transplantation: fifteenth official report
1998.
J Heart Lung Transplant
1998;
17:
656-668
[Medline].
160. Annual Report of the U.S. Scientific Registry for Transplant Recipients and the Organ Procurement and Transplantation Network. Transplant data: 1988-1994. Division of Transplantation, Health Resources and Services Administration, U.S. Department of Health and Human Services, Washington, DC. 1995.
161. Maurer JR, Frost AE, Estenne M, Higenbottam T, Glanville AR. International guidelines for the selection of lung transplant candidates. The International Society for Heart and Lung Transplantation, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society. Transplantation 1998; 66: 951-956 [Medline].
162. Regueiro CR, Hamel MB, Davis RB, Desbiens N, Connors AF Jr,, Phillips RS. A comparison of generalist and pulmonologist care for patients hospitalized with severe chronic obstructive pulmonary disease: resource intensity, hospital costs, and survival. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. Am J Med 1998; 10: 366-372 .
163. Gibson PG, Wlodarczyk JH, Wilson AJ, Sprogis A. Severe exacerbation of chronic obstructive airways disease: health resource use in general practice and hospital. J Qual Clin Pract 1998; 18: 125-133 [Medline].
164. Warren PM, Flenley DC, Millar JS, Avery A. Respiratory failure revisited: acute exacerbations of chronic bronchitis between 1961-68 and 1970-76. Lancet 1980; 1: 467-470 [Medline].
165. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204 .
166.
Wilson R.
The role of infection in COPD.
Chest
1998;
113:
242S-248S
167.
Soler N,
Torres A,
Ewig S,
Gonzalez J,
Celis R,
El-Ebiary M,
Hernandez C,
Rodriguez-Roisin R.
Bronchial microbial patterns in severe
exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation.
Am J Respir Crit Care Med
1998;
157:
1498-1505
168. Smith CB, Kanner RE, Golden CA, Klauber MR, Renzetti AD Jr.. Effect of viral infections on pulmonary function in patients with chronic obstructive pulmonary diseases. J Infect Dis 1980; 141: 271-280 [Medline].
169. MacFarlane JT, Colville A, Guion A, Macfarlane RM, Rose DH. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. Lancet 1993; 341: 511-514 [Medline].
170.
Stockley RA,
O'Brien C,
Pye A,
Hill SL.
Relationship of sputum color
to nature and outpatient management of acute exacerbations of
COPD.
Chest
2000;
117:
1638-1645
171. Anderson HR, Spix C, Medina S, Schouten JP, Castellsague J, Rossi G, Zmirou D, Touloumi G, Wojtyniak B, Ponka A, Bacharova L, Schwartz J, Katsouyanni K. Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project. Eur Respir J 1997; 10: 1064-1071 [Abstract].
172. Chodosh S, McCarty J, Farkas S, Drehobl M, Tosiello R, Shan M, Aneiro L, Kowalsky S. Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Clin Infect Dis 1998; 27: 722-729 [Medline].
173.
Walsh EE,
Falsey AR,
Hennessey PA.
Respiratory syncytial and other
virus infections in persons with chronic cardiopulmonary disease.
Am J Respir Crit Care Med
1999;
160:
791-795
174.
Mogulkoc N,
Karakurt S,
Isalska B,
Bayindir U,
Celikel T,
Korten V,
Colpan N.
Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection.
Am J Respir
Crit Care Med
1999;
160:
349-353
175. Murphy TF, Sethi S, Klingman KL, Brueggemann AB, Doern GV. Simultaneous respiratory tract colonization by multiple strains of nontypeable Haemophilus influenzae in chronic obstructive pulmonary disease: implications for antibiotic therapy. J Infect Dis 1999; 180: 404-409 [Medline].
176.
Emerman CL,
Effron D,
Lukens TW.
Spirometric criteria for hospital
admission of patients with acute exacerbation of COPD.
Chest
1991;
99:
595-599
177.
Emerman CL,
Lukens TW,
Effron D.
Physician estimation of FEV1 in
acute exacerbation of COPD.
Chest
1994;
105:
1709-1712
178. Emerman CL, Cydulka RK. Use of peak expiratory flow rate in emergency department evaluation of acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1996; 27: 159-163 [Medline].
179. Emerman CL, Connors AF, Lukens TW, Effron D, May ME. Relationship between arterial blood gases and spirometry in acute exacerbations of chronic obstructive pulmonary disease. Ann Emerg Med 1989; 18: 523-527 [Medline].
180. Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996; 154: 407-412 [Abstract].
181. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354: 456-460 [Medline].
182.
Niewoehner DE,
Erbland ML,
Deupree RH,
Collins D,
Gross NJ,
Light RW,
Anderson P,
Morgan NA.
Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease.
Department of Veterans Affairs Cooperative Study Group.
N Engl J
Med
1999;
340:
1941-1947
183. Connors AF Jr,, Dawson NV, Thomas C, Harrell FE Jr,, Desbiens N, Fulkerson WJ, Kussin P, Bellamy P, Goldman L, Knaus WA. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators. Am J Respir Crit Care Med 1996; 154: 959-967 [Abstract].
184.
Shepperd S,
Harwood D,
Gray A,
Vessey M,
Morgan P.
Randomised
controlled trial comparing hospital at home care with inpatient hospital care. II: cost minimisation analysis.
BMJ
1998;
316:
1791-1796
185. Gravil JH, Al-Rawas OA, Cotton MM, Flanigan U, Irwin A, Stevenson RD. Home treatment of exacerbations of chronic obstructive pulmonary disease by an acute respiratory assessment service. Lancet 1998; 351: 1853-1855 [Medline].
186.
Moayyedi P,
Congleton J,
Page RL,
Pearson SB,
Muers MF.
Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease.
Thorax
1995;
50:
834-837
187. Fernandez A, Munoz J, de la Calle B, Alia I, Ezpeleta A, de la Cal MA, Reyes A. Comparison of one versus two bronchodilators in ventilated COPD patients. Intensive Care Med 1994; 20: 199-202 [Medline].
188. Barbera JA, Reyes A, Roca J, Montserrat JM, Wagner PD, Rodriguez-Roisin R. Effect of intravenously administered aminophylline on ventilation/perfusion inequality during recovery from exacerbations of chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 145: 1328-1333 [Medline].
189.
Mahon JL,
Laupacis A,
Hodder RV,
McKim DA,
Paterson NA,
Wood TE,
Donner A.
Theophylline for irreversible chronic airflow limitation: a randomized study comparing n of 1 trials to standard practice.
Chest
1999;
115:
38-48
190. Lloberes P, Ramis L, Montserrat JM, Serra J, Campistol J, Picado C, Agusti-Vidal A. Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease. Eur Respir J 1988; 1: 536-539 [Abstract].
191. Murciano D, Aubier M, Lecocguic Y, Pariente R. Effects of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease. N Engl J Med 1984; 311: 349-353 [Abstract].
192. Emerman CL, Connors AF, Lukens TW, May ME, Effron D. Theophylline concentrations in patients with acute exacerbation of COPD. Am J Emerg Med 1990; 8: 289-292 [Medline].
193.
Meyer TJ,
Hill NS.
Noninvasive positive pressure ventilation to treat
respiratory failure.
Ann Intern Med
1994;
120:
760-770
194. International Consensus Conferences in Intensive Care Medicine: noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 2001;163:283-291.
195. Bott J, Carroll MP, Conway JH, Keilty SE, Ward EM, Brown AM, Paul EA, Elliott MW, Godfrey RC, Wedzicha JA, et al . Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. Lancet 1993; 341: 1555-1557 [Medline].
196.
Brochard L,
Mancebo J,
Wysocki M,
Lofaso F,
Conti G,
Rauss A,
Simonneau G,
Benito S,
Gasparetto A,
Lemaire F.
Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease.
N Engl J Med
1995;
333:
817-822
197. Kramer N, Meyer TJ, Meharg J, Cece RD, Hill NS. Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 1995; 151: 1799-1806 [Abstract].
198. Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Lancet 2000; 355: 1931-1935 [Medline].
199.
Esteban A,
Anzueto A,
Alia I,
Gordo F,
Apezteguia C,
Palizas F,
Cide D,
Goldwaser R,
Soto L,
Budego G,
Rodrigo C,
Pimentel J,
Raimondi G,
Tobin MJ.
How is mechanical ventilation employed in the
intensive care unit? An international utilization review.
Am J Respir
Crit Care Med
2000;
161:
1450-1458
200.
Esteban A,
Frutos F,
Tobin MJ,
Alia I,
Solsona JF,
Valverdu I,
Fernandez R,
de la Cal MA,
Benito S,
Tomas R,
Carriedo D,
Macias S,
Blanco J.
for the Spanish Lung Failure Collaborative Group. A comparison of four methods of weaning patients from mechanical ventilation.
N Engl J Med
1995;
332:
345-350
201. Brochard L, Rauss A, Benito S, Conti G, Mancebo J, Rekik N, Gasparetto A, Lemaire F. Comparison of three methods of gradual withdrawal from ventilatory support during weaning from mechanical ventilation. Am J Respir Crit Care Med 1994;150;896-903.
202.
Nava S,
Ambrosino N,
Clini E,
Prato M,
Orlando G,
Vitacca M,
Brigada P,
Fracchia C,
Rubini F.
Noninvasive mechanical ventilation
in the weaning of patients with respiratory failure due to chronic obstructive pulmonary disease: a randomized, controlled trial.
Ann Intern Med
1998;
128:
721-728
203. Hilbert G, Gruson D, Portel L, Gbikpi-Benissan G, Cardinaud JP. Noninvasive pressure support ventilation in COPD patients with postextubation hypercapnic respiratory insufficiency. Eur Respir J 1998; 11: 1349-1353 [Abstract].
204.
Kessler R,
Faller M,
Fourgaut G,
Mennecier B,
Weitzenblum E.
Predictive factors of hospitalization for acute exacerbation in a series of
64 patients with chronic obstructive pulmonary disease.
Am J Respir
Crit Care Med
1999;
159:
158-164
205.
Mushlin AI,
Black ER,
Connolly CA,
Buonaccorso KM,
Eberly SW.
The necessary length of hospital stay for chronic pulmonary disease.
JAMA
1991;
266:
80-83
206. Stoller JK, Lange PA. Inpatient management of chronic obstructive pulmonary disease. Respir Care Clin North Am 1998; 4: 425-438 .
207.
Peach H,
Pathy MS.
Follow-up study of disability among elderly patients discharged from hospital with exacerbations of chronic bronchitis.
Thorax
1981;
36:
585-589
208. NHS Executive. Burdens of Disease: A Discussion Document. Department of Health, London, UK.
209. Rutten-van Mölken MP, Postma MJ, Joore MA, Van Genugten ML, Leidl R, Jager JC. Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands. Respir Med 1999; 93: 779-787 [Medline].
210. Jacobson L, Hertzman P, Lofdahl C-G, Skoogh B-E, Lindgren B. The economic impact of asthma and COPD in Sweden 1980 and 1991. Respir Med 2000; 94: 247-255 [Medline].
This article has been cited by other articles:
![]() |
K. Hill, S. Patman, and D. Brooks Effect of airway clearance techniques in patients experiencing an acute exacerbation of chronic obstructive pulmonary disease: A systematic review Chronic Respiratory Disease, February 1, 2010; 7(1): 9 - 17. [Abstract] [PDF] |
||||
![]() |
L. M. Osman, J. G. Ayres, C. Garden, K. Reglitz, J. Lyon, and J. G. Douglas A randomised trial of home energy efficiency improvement in the homes of elderly COPD patients Eur. Respir. J., February 1, 2010; 35(2): 303 - 309. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. K. Andersson, M. Mori, L. Bjermer, C.-G. Lofdahl, and J. S. Erjefalt Alterations in Lung Mast Cell Populations in Patients with Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., February 1, 2010; 181(3): 206 - 217. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Profita, A. Sala, A. Bonanno, L. Riccobono, M. Ferraro, S. La Grutta, G. D. Albano, A. M. Montalbano, and M. Gjomarkaj Chronic obstructive pulmonary disease and neutrophil infiltration: role of cigarette smoke and cyclooxygenase products Am J Physiol Lung Cell Mol Physiol, February 1, 2010; 298(2): L261 - L269. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. A. Daniels, D. Snijders, C. S. de Graaff, F. Vlaspolder, H. M. Jansen, and W. G. Boersma Antibiotics in Addition to Systemic Corticosteroids for Acute Exacerbations of Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., January 15, 2010; 181(2): 150 - 157. [Abstract] [Full Text] [PDF] |
||||
![]() |
M-C. L. Machado, W. M. Vollmer, S. M. Togeiro, A. L. Bilderback, M-V. C. Oliveira, F. S. Leitao, F. Queiroga Jr, G. Lorenzi-Filho, and J. A. Krishnan CPAP and survival in moderate-to-severe obstructive sleep apnoea syndrome and hypoxaemic COPD Eur. Respir. J., January 1, 2010; 35(1): 132 - 137. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Cho, M. Fournier, X. Da, and M. I. Lewis Time course expression of Foxo transcription factors in skeletal muscle following corticosteroid administration J Appl Physiol, January 1, 2010; 108(1): 137 - 145. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Vlachaki, A. V. Koutsopoulos, N. Tzanakis, E. Neofytou, M. Siganaki, I. Drositis, A. Moniakis, S. Schiza, N. M. Siafakas, and E. G. Tzortzaki Altered Surfactant Protein-A Expression in Type II Pneumocytes in COPD Chest, January 1, 2010; 137(1): 37 - 45. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ekstrom, K. A. Franklin, and K. E. Strom Increased Relative Mortality in Women With Severe Oxygen-Dependent COPD Chest, January 1, 2010; 137(1): 31 - 36. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.-M. Sundblad, K. Larsson, and L. Nathell Lung function testing influences the attitude toward smoking cessation Nicotine Tob Res, January 1, 2010; 12(1): 37 - 42. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F. Vidal Melo, T. Winkler, R. S. Harris, G. Musch, R. E. Greene, and J. G. Venegas Spatial Heterogeneity of Lung Perfusion Assessed with 13N PET as a Vascular Biomarker in Chronic Obstructive Pulmonary Disease J. Nucl. Med., January 1, 2010; 51(1): 57 - 65. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bourdin, P-R Burgel, P. Chanez, G. Garcia, T. Perez, and N. Roche Recent advances in COPD: pathophysiology, respiratory physiology and clinical aspects, including comorbidities Eur. Respir. Rev., December 1, 2009; 18(114): 198 - 212. [Full Text] [PDF] |
||||
![]() |
E. J. R. van Beek, A. M. Dahmen, T. Stavngaard, K. K. Gast, C. P. Heussel, F. Krummenauer, J. Schmiedeskamp, J. M. Wild, L. V. Sogaard, A. E. Morbach, et al. Hyperpolarised 3He MRI versus HRCT in COPD and normal volunteers: PHIL trial Eur. Respir. J., December 1, 2009; 34(6): 1311 - 1321. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Attaran, S. M Lari, M. Khajehdaluee, H. Ayatollahi, M. Towhidi, A. Asnaashari, H. G. Marallu, M. Mazloomi, and M. B. Mood Highly sensitive C-reactive protein levels in Iranian patients with pulmonary complication of sulfur mustard poisoning and its correlation with severity of airway diseases Human and Experimental Toxicology, December 1, 2009; 28(12): 739 - 745. [Abstract] [PDF] |
||||
![]() |
K. Hellstrom, B. Vahlberg, C. Urell, and M. Emtner Fear of falling, fall-related self-efficacy, anxiety and depression in individuals with chronic obstructive pulmonary disease Clinical Rehabilitation, December 1, 2009; 23(12): 1136 - 1144. [Abstract] [PDF] |
||||
![]() |
A Zanini, A Chetta, M Saetta, S Baraldo, C Castagnetti, G Nicolini, M Neri, and D Olivieri Bronchial vascular remodelling in patients with COPD and its relationship with inhaled steroid treatment Thorax, December 1, 2009; 64(12): 1019 - 1024. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. de Marco, S. Accordini, J. M. Anto, T. Gislason, J. Heinrich, C. Janson, D. Jarvis, N. Kunzli, B. Leynaert, A. Marcon, et al. Long-Term Outcomes in Mild/Moderate Chronic Obstructive Pulmonary Disease in the European Community Respiratory Health Survey Am. J. Respir. Crit. Care Med., November 15, 2009; 180(10): 956 - 963. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Garcia-Vidal, P. Almagro, V. Romani, M. Rodriguez-Carballeira, E. Cuchi, L. Canales, D. Blasco, J. L. Heredia, and J. Garau Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study Eur. Respir. J., November 1, 2009; 34(5): 1072 - 1078. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Castaldi, D. L. DeMeo, D. M. Kent, E. J. Campbell, A. F. Barker, M. L. Brantly, E. Eden, N. G. McElvaney, S. I. Rennard, J. M. Stocks, et al. Development of Predictive Models for Airflow Obstruction in Alpha-1-Antitrypsin Deficiency Am. J. Epidemiol., October 15, 2009; 170(8): 1005 - 1013. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Pujades-Rodriguez, S Lewis, T Mckeever, J Britton, and A Venn Effect of living close to a main road on asthma, allergy, lung function and chronic obstructive pulmonary disease Occup. Environ. Med., October 1, 2009; 66(10): 679 - 684. [Abstract] [Full Text] [PDF] |
||||
![]() |
M A Arbex, G M de Souza Conceicao, S P Cendon, F F Arbex, A C Lopes, E P Moyses, S L Santiago, P H N Saldiva, L A A Pereira, and A L F Braga Urban air pollution and chronic obstructive pulmonary disease-related emergency department visits J Epidemiol Community Health, October 1, 2009; 63(10): 777 - 783. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Watz, B. Waschki, A. Kirsten, K.-C. Muller, G. Kretschmar, T. Meyer, O. Holz, and H. Magnussen The Metabolic Syndrome in Patients With Chronic Bronchitis and COPD: Frequency and Associated Consequences for Systemic Inflammation and Physical Inactivity Chest, October 1, 2009; 136(4): 1039 - 1046. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Smolonska, C. Wijmenga, D. S. Postma, and H. M. Boezen Meta-analyses on Suspected Chronic Obstructive Pulmonary Disease Genes: A Summary of 20 Years' Research Am. J. Respir. Crit. Care Med., October 1, 2009; 180(7): 618 - 631. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Jansat, R. Lamarca, G. de Miquel, A. Schrodter, B. Miletzki, and M. Gurniak Safety and Pharmacokinetics of Multiple Doses of Aclidinium Bromide, a Novel Long-Acting Muscarinic Antagonist for the Treatment of Chronic Obstructive Pulmonary Disease, in Healthy Participants J. Clin. Pharmacol., October 1, 2009; 49(10): 1239 - 1246. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. S. Wan and E. K. Silverman Genetics of COPD and Emphysema Chest, September 1, 2009; 136(3): 859 - 866. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Zhu, A. Agusti, A. Gulsvik, P. Bakke, H. Coxson, D. A. Lomas, E. K. Silverman, S. G. Pillai, and ICGN investigators CTLA4 gene polymorphisms are associated with chronic bronchitis Eur. Respir. J., September 1, 2009; 34(3): 598 - 604. [Abstract] [Full Text] [PDF] |
||||
![]() |
D Kotz, R Vos, and M J H Huibers Ethical analysis of the justifiability of labelling with COPD for smoking cessation J. Med. Ethics, September 1, 2009; 35(9): 534 - 540. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. P. Hersh, N. N. Hansel, K. C. Barnes, D. A. Lomas, S. G. Pillai, H. O. Coxson, R. A. Mathias, N. M. Rafaels, R. A. Wise, J. E. Connett, et al. Transforming Growth Factor-{beta} Receptor-3 Is Associated with Pulmonary Emphysema Am. J. Respir. Cell Mol. Biol., September 1, 2009; 41(3): 324 - 331. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Lee, C. Wilke, M. Joo, K. T. Stroupe, J. A. Krishnan, G. T. Schumock, and A. S. Pickard Outcomes Associated With Tiotropium Use in Patients With Chronic Obstructive Pulmonary Disease Arch Intern Med, August 10, 2009; 169(15): 1403 - 1410. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Brusasco Statistically significant or clinically useful? From population studies to patient care Eur. Respir. J., August 1, 2009; 34(2): 291 - 292. [Full Text] [PDF] |
||||
![]() |
E. G. Tzortzaki and N. M. Siafakas A hypothesis for the initiation of COPD Eur. Respir. J., August 1, 2009; 34(2): 310 - 315. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Demoor, K. R. Bracke, T. Maes, B. Vandooren, D. Elewaut, C. Pilette, G. F. Joos, and G. G. Brusselle Role of lymphotoxin-{alpha} in cigarette smoke-induced inflammation and lymphoid neogenesis Eur. Respir. J., August 1, 2009; 34(2): 405 - 416. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. Sommers, J. M. Thompson, J. A. Guzova, S. L. Bonar, R. K. Rader, S. Mathialagan, N. Venkatraman, V. W. Holway, L. E. Kahn, G. Hu, et al. Novel Tight-Binding Inhibitory Factor-{kappa}B Kinase (IKK-2) Inhibitors Demonstrate Target-Specific Anti-Inflammatory Activities in Cellular Assays and following Oral and Local Delivery in an in Vivo Model of Airway Inflammation J. Pharmacol. Exp. Ther., August 1, 2009; 330(2): 377 - 388. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Zvezdin, S. Milutinov, M. Kojicic, M. Hadnadjev, S. Hromis, M. Markovic, and O. Gajic A Postmortem Analysis of Major Causes of Early Death in Patients Hospitalized With COPD Exacerbation Chest, August 1, 2009; 136(2): 376 - 380. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Oldenburg, C. Bittner, and X. Baur Health Risks Due to Coffee Dust Chest, August 1, 2009; 136(2): 536 - 544. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. D. Broekhuizen, A. P. Sachs, R. Oostvogels, A. W Hoes, T. J. Verheij, and K. G. Moons The diagnostic value of history and physical examination for COPD in suspected or known cases: a systematic review Fam. Pract., August 1, 2009; 26(4): 260 - 268. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. G. Brusselle, T. Demoor, K. R. Bracke, C-A. Brandsma, and W. Timens Lymphoid follicles in (very) severe COPD: beneficial or harmful? Eur. Respir. J., July 1, 2009; 34(1): 219 - 230. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Isajevs, I. Taivans, G. Strazda, U. Kopeika, M. Bukovskis, V. Gordjusina, and A. Kratovska From the authors: Eur. Respir. J., July 1, 2009; 34(1): 285 - 286. [Full Text] [PDF] |
||||
![]() |
R J Thorpe Jr, S L Szanton, and K Whitfield Association between lung function and disability in African-Americans J Epidemiol Community Health, July 1, 2009; 63(7): 541 - 545. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. H. Sillen, C. M. Speksnijder, R.-M. A. Eterman, P. P. Janssen, S. S. Wagers, E. F. M. Wouters, N. H. M. K. Uszko-Lencer, and M. A. Spruit Effects of Neuromuscular Electrical Stimulation of Muscles of Ambulation in Patients With Chronic Heart Failure or COPD: A Systematic Review of the English-Language Literature Chest, July 1, 2009; 136(1): 44 - 61. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. van der Toorn, D. Rezayat, H. F. Kauffman, S. J. L. Bakker, R. O. B. Gans, G. H. Koeter, A. M. K. Choi, A. J. M. van Oosterhout, and D.-J. Slebos Lipid-soluble components in cigarette smoke induce mitochondrial production of reactive oxygen species in lung epithelial cells Am J Physiol Lung Cell Mol Physiol, July 1, 2009; 297(1): L109 - L114. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. K. Silverman and R. A. Sandhaus Alpha1-Antitrypsin Deficiency N. Engl. J. Med., June 25, 2009; 360(26): 2749 - 2757. [Full Text] [PDF] |
||||
![]() |
M. Plotkowiak, K. Burrowes, J. Wolber, C. Buckley, R. Davies, F. Gleeson, D. Gavaghan, and V. Grau Relationship between structural changes and hyperpolarized gas magnetic resonance imaging in chronic obstructive pulmonary disease using computational simulations with realistic alveolar geometry Phil Trans R Soc A, June 13, 2009; 367(1896): 2347 - 2369. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Rodriguez-Roisin, M. Drakulovic, D. A. Rodriguez, J. Roca, J. A. Barbera, and P. D. Wagner Ventilation-perfusion imbalance and chronic obstructive pulmonary disease staging severity J Appl Physiol, June 1, 2009; 106(6): 1902 - 1908. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Puente-Maestu, J. Perez-Parra, R. Godoy, N. Moreno, A. Tejedor, A. Torres, A. Lazaro, A. Ferreira, and A. Agusti Abnormal Transition Pore Kinetics and Cytochrome C Release in Muscle Mitochondria of Patients with Chronic Obstructive Pulmonary Disease Am. J. Respir. Cell Mol. Biol., June 1, 2009; 40(6): 746 - 750. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Petecchia, F. Sabatini, L. Varesio, A. Camoirano, C. Usai, A. Pezzolo, and G. A. Rossi Bronchial Airway Epithelial Cell Damage Following Exposure to Cigarette Smoke Includes Disassembly of Tight Junction Components Mediated by the Extracellular Signal-Regulated Kinase 1/2 Pathway Chest, June 1, 2009; 135(6): 1502 - 1512. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S.P. Lam, B. A. Borlaug, G. C. Kane, F. T. Enders, R. J. Rodeheffer, and M. M. Redfield Age-Associated Increases in Pulmonary Artery Systolic Pressure in the General Population Circulation, May 26, 2009; 119(20): 2663 - 2670. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. B. van Tilburg, H. Stam, H. C. Hoogsteden, and R. J. van Klaveren Pre-operative pulmonary evaluation of lung cancer patients: a review of the literature Eur. Respir. J., May 1, 2009; 33(5): 1206 - 1215. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Wang, Y. Liu, L. Chen, X. Wang, X-R. Hu, Y-L. Feng, D-S. Liu, D. Xu, Y-P. Duan, J. Lin, et al. Effect of sildenafil on acrolein-induced airway inflammation and mucus production in rats Eur. Respir. J., May 1, 2009; 33(5): 1122 - 1132. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Profita, A. Bonanno, L. Siena, A. Bruno, M. Ferraro, A. M. Montalbano, G. D. Albano, L. Riccobono, P. Casarosa, M. P. Pieper, et al. Smoke, Choline Acetyltransferase, Muscarinic Receptors, and Fibroblast Proliferation in Chronic Obstructive Pulmonary Disease J. Pharmacol. Exp. Ther., May 1, 2009; 329(2): 753 - 763. [Abstract] [Full Text] [PDF] |
||||
![]() |
J M Seymour, K Ward, P S Sidhu, Z Puthucheary, J Steier, C J Jolley, G Rafferty, M I Polkey, and J Moxham Ultrasound measurement of rectus femoris cross-sectional area and the relationship with quadriceps strength in COPD Thorax, May 1, 2009; 64(5): 418 - 423. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Costi, M. Di Bari, P. Pillastrini, R. D'Amico, E. Crisafulli, C. Arletti, L. M Fabbri, and E. M Clini Short-term Efficacy of Upper-Extremity Exercise Training in Patients With Chronic Airway Obstruction: A Systematic Review Physical Therapy, May 1, 2009; 89(5): 443 - 455. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Gaschler, M. Skrtic, C. C. J. Zavitz, M. Lindahl, P.-O. Onnervik, T. F. Murphy, S. Sethi, and M. R. Stampfli Bacteria Challenge in Smoke-exposed Mice Exacerbates Inflammation and Skews the Inflammatory Profile Am. J. Respir. Crit. Care Med., April 15, 2009; 179(8): 666 - 675. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Kotz, G. Wesseling, M. J. H. Huibers, and O. C. P. van Schayck Efficacy of confronting smokers with airflow limitation for smoking cessation Eur. Respir. J., April 1, 2009; 33(4): 754 - 762. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Deslee, J. C. Woods, C. Moore, S. H. Conradi, D. S. Gierada, J. J. Atkinson, J. T. Battaile, L. Liu, G. A. Patterson, T. L. Adair-Kirk, et al. Oxidative Damage to Nucleic Acids in Severe Emphysema Chest, April 1, 2009; 135(4): 965 - 974. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Shimada, N. Hiramatsu, K. Hayakawa, S. Takahashi, A. Kasai, Y. Tagawa, M. Mukai, J. Yao, Y. Fujii-Kuriyama, and M. Kitamura Dual suppression of adipogenesis by cigarette smoke through activation of the aryl hydrocarbon receptor and induction of endoplasmic reticulum stress Am J Physiol Endocrinol Metab, April 1, 2009; 296(4): E721 - E730. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Suzuki, T. Betsuyaku, Y. Ito, K. Nagai, N. Odajima, C. Moriyama, Y. Nasuhara, and M. Nishimura Curcumin attenuates elastase- and cigarette smoke-induced pulmonary emphysema in mice Am J Physiol Lung Cell Mol Physiol, April 1, 2009; 296(4): L614 - L623. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S.P. Lam, V. L. Roger, R. J. Rodeheffer, B. A. Borlaug, F. T. Enders, and M. M. Redfield Pulmonary hypertension in heart failure with preserved ejection fraction a community-based study. J. Am. Coll. Cardiol., March 31, 2009; 53(13): 1119 - 1126. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Quaak, C. P. van Schayck, A. M. Knaapen, and F. J. van Schooten Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory diseases? Eur. Respir. J., March 1, 2009; 33(3): 468 - 480. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhou, C. Wang, W. Yao, P. Chen, J. Kang, S. Huang, B. Chen, C. Wang, D. Ni, X. Wang, et al. COPD in Chinese nonsmokers Eur. Respir. J., March 1, 2009; 33(3): 509 - 518. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. de Torres, C. G. Cote, M. V. Lopez, C. Casanova, O. Diaz, J. M. Marin, V. Pinto-Plata, M. M. de Oca, H. Nekach, L. J. Dordelly, et al. Sex differences in mortality in patients with COPD Eur. Respir. J., March 1, 2009; 33(3): 528 - 535. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Marchand Effect of Pharmacotherapy on Rate of Decline of FEV1 in the TORCH Study Am. J. Respir. Crit. Care Med., March 1, 2009; 179(5): 426 - 426. [Full Text] [PDF] |
||||
![]() |
J. N. de Voogd, J. B. Wempe, G. H. Koeter, K. Postema, E. van Sonderen, A. V. Ranchor, J. C. Coyne, and R. Sanderman Depressive Symptoms as Predictors of Mortality in Patients With COPD Chest, March 1, 2009; 135(3): 619 - 625. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Cavarra, P. Fardin, S. Fineschi, A. Ricciardi, G. De Cunto, F. Sallustio, M. Zorzetto, M. Luisetti, U. Pfeffer, G. Lungarella, et al. Early response of gene clusters is associated with mouse lung resistance or sensitivity to cigarette smoke Am J Physiol Lung Cell Mol Physiol, March 1, 2009; 296(3): L418 - L429. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Watz, B. Waschki, T. Meyer, and H. Magnussen Physical activity in patients with COPD Eur. Respir. J., February 1, 2009; 33(2): 262 - 272. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bussotti, P. Agostoni, A. Durigato, C. Santoriello, S. Farina, V. Brusasco, and R. Pellegrino Do Maximum Flow-Volume Loops Collected During Maximum Exercise Test Alter the Main Cardiopulmonary Parameters? Chest, February 1, 2009; 135(2): 425 - 433. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Isajevs, I. Taivans, G. Strazda, U. Kopeika, M. Bukovskis, V. Gordjusina, and A. Kratovska Decreased FOXP3 expression in small airways of smokers with COPD Eur. Respir. J., January 1, 2009; 33(1): 61 - 67. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S Jaakkola Smoke and dust get in your eyes: what does it mean in the workplace? Thorax, January 1, 2009; 64(1): 1 - 2. [Full Text] [PDF] |
||||
![]() |
P D Blanc, C Iribarren, L Trupin, G Earnest, P P Katz, J Balmes, S Sidney, and M D Eisner Occupational exposures and the risk of COPD: dusty trades revisited Thorax, January 1, 2009; 64(1): 6 - 12. [Abstract] [Full Text] [PDF] |
||||
![]() |
J H J Vernooy, N E A Drummen, R J van Suylen, R H E Cloots, G M Moller, K R Bracke, S Zuyderduyn, M A Dentener, G G Brusselle, P S Hiemstra, et al. Enhanced pulmonary leptin expression in patients with severe COPD and asymptomatic smokers Thorax, January 1, 2009; 64(1): 26 - 32. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. O. Coxson Quantitative chest tomography in COPD research: chairman's summary. Proceedings of the ATS, December 15, 2008; 5(9): 874 - 877. [Full Text] [PDF] |
||||
![]() |
I. Rahman Review: Antioxidant therapeutic advances in COPD Therapeutic Advances in Respiratory Disease, December 1, 2008; 2(6): 351 - 374. [Abstract] [PDF] |
||||
![]() |
R. Rodriguez-Roisin and J. B. Soriano Chronic Obstructive Pulmonary Disease with Lung Cancer and/or Cardiovascular Disease Proceedings of the ATS, December 1, 2008; 5(8): 842 - 847. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Volpato, M. Cavalieri, G. Guerra, F. Sioulis, M. Ranzini, C. Maraldi, R. Fellin, and J. M. Guralnik Performance-Based Functional Assessment in Older Hospitalized Patients: Feasibility and Clinical Correlates J Gerontol A Biol Sci Med Sci, December 1, 2008; 63(12): 1393 - 1398. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Hantos, A. Adamicza, T. Z. Janosi, M. V. Szabari, J. Tolnai, and B. Suki Lung volumes and respiratory mechanics in elastase-induced emphysema in mice J Appl Physiol, December 1, 2008; 105(6): 1864 - 1872. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Suzuki, T. Betsuyaku, Y. Ito, K. Nagai, Y. Nasuhara, K. Kaga, S. Kondo, and M. Nishimura Down-Regulated NF-E2-Related Factor 2 in Pulmonary Macrophages of Aged Smokers and Patients with Chronic Obstructive Pulmonary Disease Am. J. Respir. Cell Mol. Biol., December 1, 2008; 39(6): 673 - 682. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. F. Berry, R. Bhagat, A. A. Ajelabi, and M. F. Petrini Effect of Smoking on Spirometry of African American and White Subjects Chest, December 1, 2008; 134(6): 1231 - 1236. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Rodriguez, J. Ferrer, S. Marti, J.-P. Zock, E. Plana, and F. Morell Impact of Occupational Exposure on Severity of COPD Chest, December 1, 2008; 134(6): 1237 - 1243. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Hartl, S. Krauss-Etschmann, B. Koller, P. L. Hordijk, T. W. Kuijpers, F. Hoffmann, A. Hector, E. Eber, V. Marcos, I. Bittmann, et al. Infiltrated Neutrophils Acquire Novel Chemokine Receptor Expression and Chemokine Responsiveness in Chronic Inflammatory Lung Diseases J. Immunol., December 1, 2008; 181(11): 8053 - 8067. [Abstract] [Full Text] [PDF] |
||||
![]() |
I Cerveri, A G Corsico, S Accordini, R Niniano, E Ansaldo, J M Anto, N Kunzli, C Janson, J Sunyer, D Jarvis, et al. Underestimation of airflow obstruction among young adults using FEV1/FVC <70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes Thorax, December 1, 2008; 63(12): 1040 - 1045. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Casanova, C. Cote, J. M. Marin, V. Pinto-Plata, J. P. de Torres, A. Aguirre-Jaime, C. Vassaux, and B. R. Celli Distance and Oxygen Desaturation During the 6-min Walk Test as Predictors of Long-term Mortality in Patients With COPD Chest, October 1, 2008; 134(4): 746 - 752. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Borghi-Silva, C C Oliveira, C Carrascosa, J Maia, D C Berton, F Queiroga Jr, E M Ferreira, D R Almeida, L E Nery, and J A Neder Respiratory muscle unloading improves leg muscle oxygenation during exercise in patients with COPD Thorax, October 1, 2008; 63(10): 910 - 915. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Jiang, G. L. Burke, P. L. Enright, A. B. Newman, H. G. Margolis, M. Cushman, R. P. Tracy, Y. Wang, R. A. Kronmal, and R. G. Barr Inflammatory Markers and Longitudinal Lung Function Decline in the Elderly Am. J. Epidemiol., September 15, 2008; 168(6): 602 - 610. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. I. Rennard and J. Vestbo The Many "Small COPDs": COPD Should Be an Orphan Disease Chest, September 1, 2008; 134(3): 623 - 627. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Curtis Palliative and end-of-life care for patients with severe COPD Eur. Respir. J., September 1, 2008; 32(3): 796 - 803. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Makris, N. Tzanakis, A. Damianaki, E. Ntaoukakis, E. Neofytou, M. Zervou, N. M. Siafakas, and E. G. Tzortzaki Microsatellite DNA instability and COPD exacerbations Eur. Respir. J., September 1, 2008; 32(3): 612 - 618. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Makris, S. Lazarou, M. Alexandrakis, T. V. Kourelis, N. Tzanakis, D. Kyriakou, and K. I. Gourgoulianis Tc2 Response at the Onset of COPD Exacerbations Chest, September 1, 2008; 134(3): 483 - 488. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H. van Houwelingen, N. M. Weathington, V. Verweij, J. E. Blalock, F. P. Nijkamp, and G. Folkerts Induction of lung emphysema is prevented by L-arginine-threonine-arginine FASEB J, September 1, 2008; 22(9): 3403 - 3408. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Matsuoka, Y. Kurihara, K. Yagihashi, M. Hoshino, and Y. Nakajima Airway Dimensions at Inspiratory and Expiratory Multisection CT in Chronic Obstructive Pulmonary Disease: Correlation with Airflow Limitation Radiology, September 1, 2008; 248(3): 1042 - 1049. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. H. Jung, S. J. Kim, C. Shin, and J. H. Kim The Considerable, Often Neglected, Impact of Pulmonary Tuberculosis on the Prevalence of COPD Am. J. Respir. Crit. Care Med., August 15, 2008; 178(4): 431 - 431. [Full Text] [PDF] |
||||
![]() |
S. Ying, B. O'Connor, J. Ratoff, Q. Meng, C. Fang, D. Cousins, G. Zhang, S. Gu, Z. Gao, B. Shamji, et al. Expression and Cellular Provenance of Thymic Stromal Lymphopoietin and Chemokines in Patients with Severe Asthma and Chronic Obstructive Pulmonary Disease J. Immunol., August 15, 2008; 181(4): 2790 - 2798. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. B. West, P. D. Wagner, J. A. Neder, G. L. Scano, N. L. Jones, S. G. Zakynthinos, I. Vogiatzis, L. Nici, P. M. Calverley, H. R. Gosker, et al. The major limitation to exercise performance in COPD is inadequate energy supply to the respiratory and locomotor muscles vs. lower limb muscle dysfunction vs. dynamic hyperinflation J Appl Physiol, August 1, 2008; 105(2): 758 - 762. [Full Text] [PDF] |
||||
![]() |
G. Faager, A. Stahle, and F. Larsen Influence of spontaneous pursed lips breathing on walking endurance and oxygen saturation in patients with moderate to severe chronic obstructive pulmonary disease Clinical Rehabilitation, August 1, 2008; 22(8): 675 - 683. [Abstract] [PDF] |
||||
![]() |
T. Raupach, F. Bahr, P. Herrmann, L. Luethje, K. Heusser, G. Hasenfuss, L. Bernardi, and S. Andreas Slow breathing reduces sympathoexcitation in COPD Eur. Respir. J., August 1, 2008; 32(2): 387 - 392. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Osman, J. G. Ayres, C. Garden, K. Reglitz, J. Lyon, and J. G. Douglas Home warmth and health status of COPD patients Eur J Public Health, August 1, 2008; 18(4): 399 - 405. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Proc. Am. Thorac. Soc. | Am. J. Respir. Cell Mol. Biol. |